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Abstract 
  
Animals have been used since a very long time as experimental subjects to support scientific progress and 
medical advances. Currently, various testing procedures implying animals are still being conducted within 
a broad range of scientific fields and applications, as for example the assessment of medical devices 
safety. The aim of this assessment is to investigate whether a medical device is safe for human use or 
poses a risk for patients’ health. Animal testing for that purpose is especially encouraged by regulatory 
requirements, which prerequisite however that the use of such testing is deemed necessary and justified in 
the context of a risk management process. Thus, animal models are no longer systematically used as in the 
past, but they remain a cornerstone within the delicate decision-making process related to the marketing 
of medical devices. Though, animal testing has some critical limitations, such as ethical concerns and 
relevance of animal data, which challenge its further use to that objective. A particular attention is 
therefore currently given to the development of animal-free alternatives to better support the application 
of the 3Rs Principle (replacement, reduction, refining) within this field. Unfortunately, the highly-
advanced methods and technologies being developed face barriers (e.g. validation and standardization) 
which hinder and slow down their implementation as regulatory-accepted alternatives. To overcome these 
difficulties, the process of regulatory acceptance of these alternatives may be optimized. This may be 
achieved for example by improving the cooperation, coordination and communication between the 
different stakeholders, i.e. researchers, regulatory approval bodies and industries. Mostly, a special focus 
may be set on commitment and shared effort to enhance the efficiency of that process and to establish a 
regulatory testing framework that no longer relies on animal models. 
 
Keywords: animal testing; non-animal alternatives; medical devices biological safety; toxicology; 
regulatory acceptance.  
  
 
 Resumen - Seguridad biológica de los dispositivos médicos: hacia pruebas sin animales 
 
Advocates of bullfighting state that the movement of defending bulls is a passing fad. However, this essay 
proves with historical evidence centuries of anti-bullfighting thinking, silenced in our country. Spanish anti-
bullfighting thinking dates back to the thirteenth century. Since then relevant jurists, philosophers, painters, 
clergy, military, politicians, journalists and historians have left their anti-bullfighting ideas. Women also 
have an important role in this historical journey, not only as defenders of animals in general but of bulls in 
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particular. The current Spanish society will be surprised by the weight and the existence of Spanish anti-
bullfighting thinking that has been produced along these centuries and should not be forgotten.  
 
Keywords: Anti-bullfighting thinking; bulls; bullfighting; animals; history.  
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1. Preface 
 
Significant milestones were achieved over the past within the field of medical devices. The 
development and safety assessment of these advances greatly relied on animal testing. Nowadays, the use of 
animals for such purposes is however debated in the scientific community and the society as a whole, 
especially since animals are recognized as sentient beings. Based on this consideration and given the broad 
advanced scientific knowledge currently available, the question has raised on the use of alternatives to 
animal models. The evaluation of the potential and the relevance of possible alternatives, the investigation 
of promising approaches and the establishment of implementation strategies have thus become essential in 
order to achieve the ultimate goal of animal-free testing. 
 
2.  Animals used for scientific purposes 
 
According to the most recent official report of the European Commission (EC), almost 11.5 million 
animals were used for experimental and other scientific purposes in the European Union (EU) in 20111,2. 
Even if it can be noted that this number slightly decreased in comparison to the previous study conducted in 
2008 (just above 12 million animals)3, this significant number show that animal testing is still widely used 
in science. As shown on Figure 1, animal testing is currently used in diverse fields such as in basic research, 
production and quality control, and toxicological and safety evaluation. The most commonly used animals 
are rodents (mice and rats for example), followed by cold blooded animals (fishes and amphibians for 
example), birds, rabbits and other animals (Figure 2). The following section provides information on 
research conducted using different animal species.  
                                                          
1 The next complete report on the use of animals in the Member States will be published by the European Commission in 2019 
(http://ec.europa.eu/environment/chemicals/lab_animals/legal_en.htm) (Webpage accessed on 15 May 2018) 
2 European Commission, Seventh Report on the Statistics on the Number of Animals used for Experimental and other Scientific 
Purposes in the Member States of the European Union, COM(2013) 859 final 
3 European Commission, Sixth Report on the Statistics on the Number of Animals used for Experimental and other Scientific 
Purposes in the Member States of the European Union, COM(2010) 511 final/2 
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Figure 1 Purposes of experiments using animal testing in the EU Member States. 
(Source: Seventh Report on the Statistics on the Number of Animals used for Experimental and other 
Scientific Purposes in the Member States of the European Union, report from the commission to the council 
and the European parliament, 2013) 
 
 
Figure 2 Percentages of animals used by classes in the EU Member States. 
(Source: Seventh Report on the Statistics on the Number of Animals used for Experimental and other 
Scientific Purposes in the Member States of the European Union, report from the commission to the council 
and the European parliament, 2013) 
 
2.1.  Rodents 
 
Rodents are small gnawing mammals having a pair of incisors in each of their upper and lower jaws. 
Mice, rats, squirrels, hamsters, guinea pigs and chinchillas for example are belonging to the rodent family. 
With a percentage of 76.88% (i.e. around 8.8 million of mice, rats, guinea pigs and other rodents) over all 
the animals considered for the statistical evaluation of the EC, rodents are the most used animals in 
laboratory research2. Their small size, ease of handling, low cost, short lifespan and good ability to breed in 
captivity make rodents a perfect mammal for laboratory studies. From a scientific point of view, the most 
significant advantage of using rodents (especially mice) is the high comparability between the mouse and 
the human genomes. A study performed by Mural et. al. showed for example that only 14 over 731 genes 
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located on the mouse chromosome 16 had no counterparts on the investigated human chromosomes4. This 
accounts for approximately 2% difference only. Numerous other studies focused on the mouse genome to 
gain additional knowledge on the genome itself (gene location, identification, alteration, mutation …) and 
on the understanding of its function sequences (gene transcription, replication …)5,6. All those investigations 
performed in the last decades led to the development of well-established experimental mouse models. As a 
consequence, these models are nowadays used by the scientific community in a wide range of experiments.  
In basic research, mice are used for example to study the physiology of small mammals. This covers 
the study of the cardiovascular, respiratory, digestive and renal systems as well as fundamental biological 
mechanisms such as regulatory systems (thermoregulation, water regulation…)7,8,9. In biomedical research, 
research on rodents mainly focuses on the study of human diseases. Rodents can suffer from diverse same 
diseases as humans do (for example diabetes), and other diseases and pathologies can be induced in mice by 
manipulating their genes. Gene manipulation consists in inducing the mutation, loss, under-expression or 
over-expression of a gene in the mouse genome, or adding a new gene to it10. Genetically engineered mice 
are commonly created by modifying the mouse embryonic stem cells with human DNA before injecting 
them into blastocyst (pre-embryonic cell structure) or by injecting a DNA sequence containing a specific 
gene into mouse embryo cells11,12. Genetically engineered mice are nowadays extensively used within 
research. They offer scientists the possibility to acquire understanding on disease processes and to work on 
the development of new preventive, therapeutic and curing treatments for different diseases13,14. One 
example of such work is the development of new drugs and their testing. Such testing is mainly used to 
predict human response to drugs. Rodents are thus often used to investigate the role of these drugs for a 
broad range of applications: anti-inflammatory drugs for Alzheimer disease15, anti-hyperglycaemic drugs for 
diabetes disease16, anti-hypertensive drugs for cardiovascular disease17 and others. Another example of 
research line for therapeutic medicine has emerged since the last two decades: the stem cell research. One of 
the ideas behind this research is that functional stem cells can be transplanted when original stem cells are 
damaged or destroyed by an injury or a disease18,19.  This seems to be a promising approach but thorough 
studies are still required before achieving treatment implementation.  
 
 
(Source: https://animaldiversity.org/) 
                                                          
4 Mural R. J. et al., A Comparison of Whole-Genome Shotgun-Derived Mouse Chromosome 16 and the Human Genome, Science 
(2002), Vol. 296, 1661-1671 
5 Georgi B. et al., From Mouse to Human: Evolutionary Genomics Analysis of Human Orthologs of Essential Genes, PLoS Genetics 
(2013), Vol 9(5), e1003484 
6 Yue F. et al., A comparative encyclopedia of DNA elements in the mouse genome, Nature (2014), Vol 515, 355-364 
7 Fox J. et al, The Mouse in Biomedical Research: Normative Biology, Husbandry, and Models (2006), Academic Press 
8 Meneton P. et al., Renal physiology of the mouse, American Journal of Physiology – Renal Physiology (2000), Vol. 278 (3), F339-
F351 
9 Hodges M. R. et al., Defects in Breathing and Thermoregulation in Mice with Near-Complete Absence of Central Serotonin 
Neurons, The Journal of Neuroscience (2008), Vol. 28(10), 2495–2505 
10 Walrath J. C. et al., Genetically Engineered Mouse Models in Cancer Research, Advances in Cancer Research (2010), Vol. 106, 
113–164  
11 Kumar T. R. et al., Transgenic Mouse Technology: Principles and Methods, Methods in Molecular Biology (2009), Vol. 590, 
335–362 
12 Physicians committee for responsible medicine, Genetically Modified Mice, PCRM.org (2014), 13187-TOX, 1-3 
13 Doiron B. et al., Beta Cell Formation in vivo Through Cellular Networking, Integration and Processing (CNIP) in Wild Type 
Adult Mice, Current Pharmaceutical Biotechnology (2016), Vol. 17, 376-388 
14 Vandamme T., Use of rodents as models of human diseases, Journal of Pharmacy and BioAllied Sciences (2014), Vol. 6(1): 2–9 
15 McGeer M. L., NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies, Neurobiology of Aging 
(2007), Vol. 28, 639–647 
16 Moller D. E., New drug targets for type 2 diabetes and the metabolic syndrome, Nature (2001), Vol. 414, 821-827 
17 Sabino B. et al., Effects of Antihypertensive Drugs on Capillary Rarefaction in Spontaneously Hypertensive Rats: Intravital 
Microscopy and Histologic Analysis, Journal of Cardiovascular Pharmacology (2008), Vol. 51, 402–409 
18 Guasch G. and Fuchs E., Mice in the world of stem cell biology, Nature Genetics (2005), Vol. 37(11), 1201–1206 
19 Deep A. et al., Mouse models of spinal cord injury and stem cell transplantation, Translational Research in Anatomy 1 (2015), 2-
10 
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2.2.  Cold blooded animals 
 
Cold blooded animals are animals which blood temperature varies with the external environmental 
temperature. These animals include fishes, amphibians, reptiles, insects and arachnids20. They represent 
12.47% of the animals used for experimental and scientific purposes according to the EC statistical 
evaluation (i.e. around 1.4 million of animals)2. Cold blooded animals are the second most used animals 
after rodents. They are used for diverse research lines depending on their characteristics. Zebra-fishes for 
example have become increasingly important. This animal model has gained interest of researchers due to 
their ease of housing and care, fully sequenced genome, genetic similarity to humans, high fertility, fast 
embryonic development and transparency of the embryos21,22. Zebra-fishes are particularly used in studies 
aiming to assess chemical toxicity and, as for rodents, to study human diseases and genetics23,24. Another 
more recent interesting research line is the understanding of organ regeneration processes (cellular and 
molecular mechanisms) such as those related to heart regeneration for example25,26. Given the potential and 
perspectives of novel research studies that offer the zebra-fish model, it is expected that the significant 
development of models utilising this species will continue to happen in the near future27,28,29,30,31. Frogs are 
also used for organ regeneration research32 but they are rather used for studying biological mechanisms 
related to reproduction (in particular endocrinology) and embryonic development33,34. Reptiles are not 
extensively used for research studies but they slowly gain interest of scientists. Up to now, the research 
involving reptiles mainly focused on physiological studies and the unique substances they produce35,36. 
 
 
(Source: https://animaldiversity.org/) 
 
                                                          
20 Although used for research studies (flies in genetics for example), insects and arachnids are not discussed within this section since 
their use is not regulated by Directive 2010/63/EU on the protection of animals used for scientific purposes and not considered 
within the report on the statistics on the number of animals used for experimental and other scientific purposes in the member states 
of the European Union. 
21 Lardelli M. Using zebrafish in human disease research: some advantages, disadvantages and ethical considerations, in: 
Proceedings of 2008 ANZCCART Conference, Auckland, New Zealand, 23-28  
22 Howe K. et al., The zebrafish reference genome sequence and its relationship to the human genome, Nature (2013), Vol. 496, 
498–503 
23 Deep A. et al., Mouse models of spinal cord injury and stem cell transplantation, Translational Research in Anatomy 1 (2015), 2-
10 
24 Santoriello C. et al., Hooked! Modeling human disease in zebrafish, The Journal of Clinical Investigation (2012), Vol. 122(7), 
2337-2343 
25 WenChao S. et al., Using zebrafish as the model organism to understand organ regeneration, Science China Life Sciences (2015), 
Vol. 58, 343–351 
26 Kikuchi K., Advances in understanding the mechanism of zebrafish heart regeneration, Stem Cell Research (2014), Vol. 13, 542-
555 
27 Jen J. et al., Zebrafish models of cancer: progress and future challenges, Current Opinion in Genetics & Development (2014), Vol. 
24, 38–45 
28 Gutiérrez-Lovera C. et al., The Potential of Zebrafish as a Model Organism for Improving the Translation of Genetic Anticancer 
Nanomedicines, Genes (2017), Vol. 8(349), 1-20 
29 Stewart A. M. et al., Zebrafish models for translational neuroscience research: from tank to bedside, Trends in Neurosciences 
(2014), Vol. 37(5), 264–278 
30 Kalueff A. V. et al., Zebrafish as an emerging model for studying complex brain disorders, Trends in Pharmacological Sciences 
(2014), Vol. 35(2), 63–75 
31 Shen C. and Zuo Z. Zebrafish as a Model to Study Autism Spectrum Disorder Caused by Environmental Chemicals Exposure, 
Journal of Alzheimer’s Disease & Parkinsonism (2016), Vol. 6(6), 1000288 
32 Diaz Quiror J. F. et al., Spinal cord regeneration: where fish, frogs and salamanders lead the way, can we follow?, Biochemical 
Journal (2013), Vol. 451, 353–364 
33 Wallingford J.B. et al., Convergent Extension: The Molecular Control of Polarized Cell Movement during Embryonic 
Development, Developmental Cell (2002), Vol. 2, 695–706 
34 Hayes T. B. et al., Atrazine induces complete feminization and chemical castration in male African clawed frogs (Xenopuslaevis), 
PNAS (2010), Vol. 107(10), 4612-4617 
35 Willmore W. G. et al., Purification and properties of glutathione reductase from liver of the anoxia-tolerant turtle, 
Trachemysscriptaelegans, Molecular and Cellular Biochemistry (2007), Vol. 297, 139–149 
36 Santos B. F. et al., Interaction of viper venom serine peptidases with thrombin receptors on human platelets, FEBS Letters 477 
(2000), 199-202 
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2.3.  Birds 
 
Birds constitute the third most used animals in research laboratories. Approximately 680 000 birds 
(5.88% of the animals used) were used for experimental and scientific purposes in 2011 according to the EU 
statistics2. Birds are experimental models that raised scientist interest for studying aging as they possess an 
outstanding resistance against aging degenerative processes.  Their lifespan is up to three times as long as an 
average mammal of comparable size. The most common domesticated species for studying aging are the 
budgerigars, the canaries and the zebra finches37,38. In addition to aging, some birds are also used to study 
physiology, neurobiology, cognition and behaviour39. A particular attention is also currently given to 
chicken, especially the embryos. Chick embryos are used to test for example the response of tissue reactions 
to biomaterials40, to study organ development41 and to assess invasive diseases such as cancer42. Thus, the 
knowledge acquire so far on birds currently enables scientists to perform studies on a variety of research 
areas. 
 
 
(Source: https://animaldiversity.org/) 
 
2.4.  Mammals (other than rodents and primates) 
 
After rodents, rabbits are the second most popular mammal used for experimental and scientific 
purposes. They account for 3.12% of the animals used in the EU in 2011 (approximately 360 000 rabbits)2. 
There are two main scientific areas that use rabbits as investigation tools: research on diseases and 
immunology, and safety testing.  Vaccination against infectious diseases and therapeutic strategies based on 
rabbit antibodies to detect or treat diseases (e.g. cancer) are currently under intensive assessment43,44,45. For 
safety testing, rabbits are mostly subjected to procedures aiming to study skin and eye irritation after contact 
with medical, pharmaceutical and chemical products for example46. With a percentage of 1.28%, artio- and 
perisso-dactyla-animals (horses, donkeys, zebras, deer, cows, sheep …) seem to have also gained the 
interest of researchers. Goats and sheep for example are important for orthopaedic research. They are often 
used to verify that an implant is functioning as intended (i.e. mechanical function, osseo-integrative 
function, regenerative function …)47,48,49. Dog is also a recognized model for this purpose since it has been 
shown that they have a similar bone structure as humans47. The amount of companion animals used is 
obviously lower than other animals due to ethical concerns but they are involved in a wide range of studies. 
These studies encompass the development of implant, the study of sensory systems and neuroscience, and 
                                                          
37 Holmes D. and Martin K., A Bird's-Eye View of Aging: What's in it for Ornithologists?, The Auk (2009), Vol. 126(1), 1–23 
38 Austad S. N., Candidate Bird Species for Use in Aging Research, ILAR Journal (2011), Vol. 52(1), 89-96 
39 Bateson M. and Feenders G., The Use of Passerine Bird Species in Laboratory Research: Implications of Basic Biology for 
Husbandry and Welfare, ILAR Journal (2010), Vol. 51(4), 395-408 
40 Valdes T. I. et al., The chick chorioallantoic membrane as a novel in vivo model for the testing of biomaterials, Journal of 
Biomedical Materials Research (2002), Vol. 62(2), 273-282 
41 Vergara M.N. and Canto-Soler M. V., Rediscovering the chick embryo as a model to study retinal development, Neural 
Development (2012), Vol. 7(22), 1-19 
42 Busch C. et al., The Chick Embryo as an Experimental System for Melanoma Cell Invasion, PLOS one (2013), Vol. 8(1), e53970 
43 Peng X. et al., Rabbit Models for Studying Human Infectious Diseases, Comparative Medicine (2015), Vol. 65(6), 499-507 
44 Feng L. et al., Rabbit monoclonal antibody: potential application in cancer therapy, American Journal of Translational Research 
(2011), Vol. 3(3), 269-274 
45 Weber J. et al., From rabbit antibody repertoires to rabbit monoclonal antibodies, Experimental & Molecular Medicine (2017), 
Vol. 49, e305 
46 Luechtefeld T. et al., Analysis of Draize Eye Irritation Testing and its Prediction by Mining Publicly Available 2008–2014 
REACH Data, ALTEX (2016), Vol. 33(2), 123–134 
47 Pearce A. I. et al., Animal models for implant biomaterial research in bone: a review, European Cells and Materials (2007), Vol. 
13, 1-10 
48 Nair M. B. et al., Treatment of Goat Femur Segmental Defects with Silica-Coated Hydroxyapatite—One-Year Follow-Up, Tissue 
Engineering: Part A (2010), Vol. 16 (2), 385-391 
49 Ryugo D. K. et al., Restoration of Auditory Nerve Synapses in Cats by Cochlear Implants, Science (2005), Vol. 310, 1490-1492 
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the elaboration of new treatments for diseases49,50,51. 
 
 
(Source: https://animaldiversity.org/) 
 
2.5.  Non-human primates 
 
Non-human primates are the animals the least used for research purposes in the EU. According to the 
report of the European Commission and the scientific committee on Health Environmental and Emerging 
Risks, they account for 0.05% of the animals used in 2011 and for 8898 procedures conducted in 20142,52. 
The most used non-human primates are cynomolgus monkeys (7098 procedures), marmosets and tamarins 
(743 procedures), rhesus monkeys (612 procedures), and baboons (183 procedures). Non-human primates 
are mainly used in procedures aiming to develop and test the safety of pharmaceuticals and medical devices 
(e.g. assessment of toxicity), to prevent or treat infectious diseases (e.g. development of vaccines), to 
advance knowledge in neuroscience (e.g. assessment of brain structure and functions), to develop therapies 
for vision debilitation (e.g. testing of gene therapies strategies) and to investigate xenotransplantation (e.g. 
establishment of methodologies)52. Despite their controversial use as experimental subjects, non-human 
primates are considered the best model to assess specific research questions due to their close genetics 
similarities with humans.  
 
 
(Source: https://animaldiversity.org/) 
 
3. Animal testing and development of medical devices 
 
As described in the previous section, scientists use a significant number of animals, from different 
species, to conduct fundamental and applied research. Most of the studies performed are conducted toward 
the improvement of human health. The advances achieved in the medical field until today are considerable, 
and animal testing is often claimed to have significantly contributed to this success. The following section 
describes some of the medical advances successfully developed by means of animal testing, with a special 
focus on medical devices. 
 
3.1.  Catheters 
 
Catheters are flexible tubular medical devices that, among other applications, can be introduced into 
vessels and cavities to deliver medications and withdraw fluids from the body (Figure 3). They are 
frequently used in urological, cardiovascular and gastrointestinal surgical procedures for example53,54. The 
                                                          
50 Nagy L. J. et al., Photorefractive keratectomy in the cat eye: biological and optical outcomes, Journal of Cataract & Refractive 
Surgery (2007), Vol. 33(6), 1051–1064 
51 Kornegay J. N. et al., Canine Models of Duchenne Muscular Dystrophy and Their Use in Therapeutic Strategies, Mammalian 
Genome (2012), Vol. 23(0), 85–108 
52 Scientific Committee on Health Environmental and Emerging Risks, Final Opinion on ‘The need for  
non-human primates in biomedical research, production and testing of products and devices (update 2017)’ (2017) 
53 Feneley R. C. L. et al., Urinary catheters: history, current status, adverse events and research agenda, Journal of Medical 
Engineering and Technology (2015), Vol. 39(8), 459–470  
54 Nossaman B. D. et al., History of Right Heart Catheterization: 100 Years of Experimentation and Methodology Development, 
Cardiology in Review (2010), Vol. 18(2), 94–101 
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history of catheter development started very long time ago with the interest for fluids and solutions 
transfusions55. Back that time, animal experimentation was extensively performed; mainly with dogs. 
Studies consisted in using needles and catheters to transfuse blood or other substances. Nevertheless, the 
real boom of catheter development took place in the twentieth century when invasive surgical procedures 
started to develop significantly. In 1844, Claude Bernard performed the first cardiac catheterization on a 
horse54. This achievement was followed in 1929 by the first cardiac catheterization performed on a living 
person by Werner Forsmann (on his own heart)54. Such procedures required advanced catheters and since 
then, continuous improvements were made on those disposable devices. This is how catheters became 
indispensable tools in the current medicine practices.  
 
 
Figure 3 Example of a catheter used in urology (Foley catheter) currently on the market. 
(Source: https://www.medline.com/product/Pediatric-100-Silicone-Foley-Catheters/Foley-Catheters/Z05-
PF148266) 
 
3.2.  Pacemakers  
 
Artificial pacemakers are implantable devices that restore the heart’s native electrical rhythm when 
the normal rhythm is impaired or stopped (Figure 4). It is able to control the cardiac activity by generating 
electrical impulse to the heart. This revolutionary device was initially developed after the Second World 
War by John Hopps as an external device56,57. His device was equipped with an external unit for cardiac 
activity monitoring and a bipolar catheter electrode which delivered the electrical impulse. Positive results 
were obtained when testing the device on dogs but it failed when testing it on humans58. The control of 
cardiac activity by means of a pacing device was finally achieved few years later after numerous further 
studies on dogs. The first implantable pacemaker, developed by William Chardack, Andrew Gage and 
Wilson Greatbatch, was successfully implanted in human in 196057,58.  This success marked the beginning of 
the pacemaker clinical use and the golden age of implantable pacemaker development.  
 
 
Figure 4 Example of a pacemaker currently on the market. 
(Source: http://www.medtronic.com/us-en/patients/treatments-therapies/pacemakers/our.html) 
 
3.3.  Hip prosthesis  
 
Hip prosthesis is an implant used in hip replacement surgeries. It is implanted when the natural hip 
joint is no longer able to support its function or is damaged (Figure 5). The development of hip prosthesis 
                                                          
55 Rivera A. M. et al., The history of peripheral intravenous catheters: How little plastic tubes revolutionized medicine, 
ActaAnaesthesiologicaBelgica (2005), Vol. 56, 271-282 
56 Bains P. et al., John Hopps and the pacemaker: A history and detailed overview of devices, indications, and complications, BC 
Medical Journal (2017), Vol. 59(1), 29-37 
57Aquilina O. A brief history of cardiac pacing, Images in Paediatric Cardiology – Journals (2006), Vol. 8(2), 17–81 
58 Mittal T. Pacemakers – A journey through the years, Indian Journal of Thoracic and Cardiovascular Surgery (2005), Vol. 21(3), 
236–249 
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has started to revolutionize the orthopaedic field in the 40’s/50’s. At this time, several scientists (Robert 
Judet, Jean Judet, Frederick Röeck Thompson, Austin Moore …) were assessing the possibility to perform 
hip arthroplasty59,60. The valuable studies they conducted constituted the basis of hip replacement 
development as driven by John Charnley between the 60’s and 80’s61. As reflected by one of his famous 
study on the lubrication of animal joints, a great part of Charnley’s work was focusing on animals62. Today, 
this has not changed: animal testing is still the testing of choice in orthopaedic research to assess hip 
prosthesis and refine replacement procedures. Animals are used for example to evaluate the 
biocompatibility, the safety and the effectiveness of new developed devices. To do so, a broad range of 
animals are used: sheep, goats, rats, mice, horses, pigs, and mostly dogs and rabbits47,63. Animal models 
were, and are still, considered an essential component in the establishment of what is nowadays known as 
the most successful orthopaedic surgery.  
 
 
Figure 5 Example of a hip prosthesis currently on the market. 
(Source: http://www.zimmerbiomet.com/medical-professionals.html) 
 
3.4.  Dialysis machine  
 
Kidneys are organs that filter blood to remove toxins and extra fluids from the body by means of 
urine production64. Kidney failure may happen to any person and constitutes a serious problem because 
kidneys have a vital function. The need for treating patients with kidney failure raised much earlier than the 
20th century but significant progresses were made in 1914 and 194565. In 1913, John Abel reported in a 
study the possibility to perform ex vivo blood dialysis and return the blood to living animals65,66. In 1945, 
Willem Kolff was the first to treat a human patient who suffered from acute renal failure65,67. The developed 
setup was initially referenced as ‘artificial kidney’ but was later named ‘dialysis machine’ (Figure 6). 
History shows that most of the experiments leading to the development of dialysis machines were performed 
using dogs and rabbits. Current research on dialysis machines still uses animals and focuses nowadays on 
improving patients’ quality of life68. The replacement of lost functions of a key organ as a kidney was a 
substantial achievement in medicine and contributes nowadays to saving many lives around the world every 
                                                          
59 Gomez P. F. and Morcuende J. A. Early attempts at hip arthroplasty: 1700s to 1950s, Iowa Orthopaedic Journal (2005), Vol. 25, 
25-29.  
60 Pramanik S. et al., Chronology of total hip joint replacement and materials development, Trends in Biomaterials and Artificial 
Organs (2005), Vol. 19(1), 15-25 
61 Gomez P. F. and Morcuende J. A historical and economic perspective on Sir John Charnley, Chas f. Thackray limited, and the 
early arthoplasty industry, The Iowa Orthopaedic Journal (2005), Vol. 25, 30–37. 
62 Charnley J. The lubrication of animal joints in relation to surgical reconstruction by arthroplasty, Annals of the Rheumatic 
Diseases (1960), Vol. 19, 10-19 
63 Sumner D. R. et al., Animal models relevant to cementless joint replacement, Journal of Musculoskeletal and Neuronal 
Interactions (2001), Vol. 1(4), 333-345 
64 Botting J. H. Development of Dialysis to Treat Loss of Kidney Function, Animals and Medicine: The Contribution of Animal 
Experiments to the Control of Disease, Cambridge: Open Book Publishers (2015), 79-86 
65 Cameron J. S. The prehistory of haemodialysis as a treatment for uraemia, GiornaleItaliano di Nefrologia (2016), Vol. 33(S66), 
ISSN 1724-5590 
66 Abel J. et al., On the removal of diffusible substances from the circulating blood of living animals by dialysis, Journal of 
Pharmacology and Experimental Therapeutics  January (1914) , Vol. 5(3),  275-316 
67 Vienken J. ‘Bioengineering for life’: a tribute to Willem Johan Kolff, Nephrology Dialysis Transplantation (2009), Vol. 24, 2299–
2301 
68 Davenport A. Portable and wearable dialysis devices for the treatment of patients with end-stage kidney failure: Wishful thinking 
or just over the horizon?, Pediatric Nephrology (2015), Vol. 30, 2053–2060 
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day.  
 
 
Figure 6 Example of a dialysis machine currently on the market. 
(Source: http://www.dialifegroup.com/dialysis-devices.html#dialysismachines) 
 
3.5.  Magnetic resonance imaging device 
 
Magnetic resonance imaging (MRI) device is a high performance machine that enables the imaging of 
tissues and organs, and the study of the physiological mechanisms of the body (Figure 7). The basics 
concepts of this technological innovation were laid down by Raymond V. Damadian, Paul C. Lauterbur and 
Peter Mansfield in the 70’s69,70. Animal testing performed for the development of MRI relied on clam, mice, 
rats, rabbits and even dogs70,71. Depending on the aim of the studies, animals were used alive or dead. They 
were used for example to demonstrate the feasibility of tracing the flow of specific agents in the body to 
improve imaging contrast, and to analyse their healthy or damaged organs (e. g. infarcted heart). Since its 
application in the early 80’s in clinical activities, MRI has turned into a very-well established imaging 
method and became a significant asset for biomedical investigations in humans. Given that different organs 
and tissues provide different contrast on a MRI scan, it is possible to visualize potential pathological 
processes or organ/tissue abnormalities on the image. Thus, MRI is nowadays a powerful tool in medical 
diagnosis and the detection of diseases such as cancer (tumor)72.   
 
 
Figure 7 Example of a MRI device currently on the market. 
                                                          
69 Hayden M. E. and Nacher P. J. History and physical principles of MRI, Magnetic Resonance Imaging Handbook, CRC Press 
(2016), Chapter 1  
70 de Haën C. Conception of the First Magnetic Resonance Imaging Contrast Agents: A Brief History, Topics in Magnetic 
Resonance Imaging (2001), Vol. 12(4), 221–230 
71 Geva T. Magnetic Resonance Imaging: Historical Perspective, Journal of Cardiovascular Magnetic Resonance (2006), Vol. 8, 
573–580 
72 Choyke P. L. Functional Tumor Imaging With Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Journal of magnetic 
resonance imaging (2003), Vol. 17, 509–520 
Medical Devices Biological Safety Assessment: Towards Animal-free Testing Nadège Sachot - Augusto Vitale 
          Derecho Animal. Forum of Animal Law Studies, vol. 10/1          101 
     
  
(Source: https://www.healthcare.siemens.ch/magnetic-resonance-imaging/3t-mri-scanner) 
 
3.6.  Cochlear implant 
 
A cochlear implant is used to treat patients who are suffering from deafness or severe losses in 
hearing73. It is a surgically implanted device that electrically stimulates the neurons of the auditory nerve by 
converting sound into an electrical current (Figure 8)74. The early invention of this implant started in 1957 
with André Djourno and Charles Eyriès who succeeded to excite the human auditory nerve for the first 
time73,74. The first cochlear implant was implanted by William House and John Doyle four years later73,74. 
Following this achievement, animal studies were conducted to optimize and develop the device. Cats have 
been used for example to explore the sound and electrical stimulations of the ear and to assess the 
biocompatibility of cochlear implant electrodes73. Nowadays, research studies still involve cats but other 
models such as ferrets, gerbils, guinea pigs and miniature pigs have also gained increasing attention in the 
last year73,75,76,77. These animal models are opening potential new research perspectives for the further 
improvement of cochlear implants77; implants which have revolutionized the field of otology by providing 
patients the restoration of their auditory sense. 
 
 
Figure 8 Example of a cochlear implant currently on the market (left: implant’s external part, right: 
implant’s internal part). 
(Source:https://www.cochlear.com/us/for-professionals/products/cochlear-implants/products) 
 
4. European Union Legal Framework of Medical Devices Biological Safety  
 
Based on the European Union Legislation, medical devices are defined as78: 
“any instrument, apparatus, appliance, software, material or other article, whether used alone or in 
combination, together with any accessories, including the software intended by its manufacturer to be used 
specifically for diagnostic and/or therapeutic purposes and necessary for its proper application, intended by 
the manufacturer to be used for human beings for the purpose of:  
 
• diagnosis, prevention, monitoring, treatment or alleviation of disease, 
• diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap, 
• investigation, replacement or modification of the anatomy or of a physiological process,  
• control of conception,  
 
and which does not achieve its principal intended action in or on the human body by pharmacological, 
                                                          
73 Eshraghi A. A. et al., The cochlear implant: Historical aspects and future prospects, The Anatomical Record (Hoboken) (2012), 
Vol. 295(11), 1967–1980 
74 Mudry A. and Mills M. The Early History of the Cochlear Implant, JAMA Otolaryngology – Head and Neck Surgery (2013), Vol. 
139(5), 446-453 
75 Kretzmer E. A et al., An Animal Model for Cochlear Implants, Archives of Otolaryngology – Head and Neck Surgery (2004), 
Vol. 130, 499-508 
76 Hartley D. E. H. et al., Bilateral cochlear implantation in the ferret: A novel animal model for behavioural studies, Journal of 
Neuroscience Methods (2010), Vol. 190(2), 214-228 
77 Yi H. et al., Miniature pigs: a large animal model of cochlear implantation, American Journal of Translational Research (2016), 
Vol. 8(12), 5494-5502 
78 European Commission, Council Directive, Directive 2007/47/EC amending Council Directive 90/385/EEC on the approximation 
of the laws of the Member States relating to active implantable medical devices, Council Directive 93/42/EEC concerning medical 
devices and Directive 98/8/EC concerning the placing of biocidal products on the market, Official Journal of the European Union 
(2007),  
L 247/21 
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immunological or metabolic means, but which may be assisted in its function by such means”.  
The term ‘medical devices’ covers thus a wide range of products, ranging from single-use compresses to 
high-technology diagnostic devices such as the magnetic resonance imaging machine (see section 3). When 
developing a medical device, three main aspects have to be considered: the efficacy of the product, its 
quality and its safety. Those aspects must be ensured following regulatory guidance and are often linked to 
animal testing, in particular when assessing the product safety. The following section reviews the current 
status of regulatory guideline applicable to medical devices marketed in the EU and to the protection of 
animals used for scientific purposes. 
 
4.1.  Council Directives applicable to medical devices 
 
Council directives are official guidance documents dealing with various subject matters that aim to 
define objectives to be reached by the EU Member States. Directives for medical devices set a regulatory 
framework that defines the essential requirements that medical devices shall fulfil to be marketed in the EU. 
Currently, three directives are in force: 
 
• Council Directive 90/385/EEC on Active Implantable Medical Devices (AIMDD) (1990)79 
• Council Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDMD) (1998)80 
• Council Directive 93/42/EEC on Medical Devices (MDD) (1993)81 
 
The definition of active medical devices is provided in Directive 90/385/EEC (AIMDD) as “any 
medical device relying for its functioning on a source of electrical energy or any source of power other than 
that directly generated by the human body or gravity”. Active medical devices may be implanted, meaning 
that they can be “totally or partially introduced, surgically or medically, into the human body or by medical 
intervention into a natural orifice” and are “intended to remain after the procedure”79. Active implantable 
devices described in the introduction are for example pacemakers and some catheters. 
The Directive 98/79/EC (IVDMD) covers in vitro diagnostic medical devices, i.e. “any medical 
device which is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, 
equipment, or system, whether used alone or in combination, intended by the manufacturer to be used in 
vitro for the examination of specimens, including blood and tissue donations, derived from the human body, 
solely or principally for the purpose of providing information concerning a physiological or pathological 
state, or concerning a congenital abnormality, or to determine the safety and compatibility with potential 
recipients, or to monitor therapeutic measures”80. Typical examples of such devices are reagents used in 
pregnancy test and kit for blood analysis.  
 The medical devices not covered by the two Directives described above falls under the Directive 
93/42/EEC. This Directive covers the largest amount of medical devices, making this Directive the main 
Directive regulating medical devices.  It encompasses ophthalmic devices, dental products, disposables, 
hospital equipment and many others. Concrete examples of such devices mentioned in the introduction are 
hip and cochlear implants.   
 Medical devices legislation has for ultimate objective to guarantee optimal patient health care and 
safety. The main challenge is to ensure that the technological progresses and innovations do not interfere 
with safety. To do so, the Directives laid down requirements with which Member States shall comply. 
Directive documents are ‘only’ guidelines, but Member States shall adopt and publish their own laws, 
regulations and administrative provisions in order to comply with them. Only devices complying with the 
relevant Directive and national rules can be approved for placement on the EU market. Directives regulate 
numerous aspects related to the life cycle of medical devices. It lists requirements from the device 
development phase to its performance within its final application. For implantable devices, incidents 
occurring after device implantation even have to be controlled (post market surveillance, complaint 
handling). Controls defined in the directives are associated to: 
 
                                                          
79 European Commission, Council Directive, Directive 90/385/EEC on the approximation of the laws of the Member States relating 
to active implantable medical devices, Council Directive, Official Journal of the European Union (1990), 1990L0385 
80 European Commission, Council Directive, Directive 98/79/EC on in vitro diagnostic medical devices, Official Journal of the 
European Union (1998), 1998L0079 
81 European Commission, Council Directive, Directive 93/42/EEC concerning medical devices, Official Journal of the European 
Union (1993), L 169/1 
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• Essential requirements related to the device design and construction: material intrinsic properties, 
materials combinations compatibility, infection and microbial contamination, protection against 
radiation, instruction for use, labelling. 
• Conformity: quality system in place, surveillance/inspections performed by notified bodies (entities 
accredited to verify that products fulfil the established requirements), correct classification of the 
device (depending on device features and application), CE marking, clinical evaluations.  
• Examination: review of the available device documentation by notified bodies and evaluation of 
product conformity. 
• Verification procedure:  Declarations of the manufacturer that products are conform to the 
examination, provisions to prove homogeneous production of the devices, testing of devices by the 
notified body to verify conformity. 
 
The overall assessment of medical devices is based on a risk/benefit analysis. This means that the 
benefits of a product must outweigh the risks existing by using the device. This implies that the risks 
associated to the design, manufacturing and packaging of the device must be minimized or reduced to an 
extent that the clinical conditions and safety of the patient is not impaired. The level of health protection and 
safety can only be guaranteed when the remaining risks are considered acceptable. Risk management is one 
of the essential tasks conducted by medical device suppliers to deliver the best innovative technologies and 
safest products.  
 
4.2.  ISO standard applicable to medical devices biological evaluation 
 
One of the key concepts of medical device safety is the demonstration of the device biocompatibility. 
Biocompatibility is the “ability of a material to perform with an appropriate host response in a specific 
application”82. In other words, biocompatibility testing aims to protect patients from potential biological 
hazards (bacteria, viruses, bio-toxins …), chemicals or fragments particles for example that could harm their 
health.  
To assess biocompatibility of medical devices, a biological evaluation consisting of a comprehensive 
set of tests is conducted. This evaluation is regulated by a series of standards very well-known in the 
medical device field and published by the International Organization for Standardization: the ISO 10993.  
This standard has for objective to provide guideline for the characterization of medical devices in order to 
evaluate their biological safety. It does not specify pass/fail criteria nor defines a rigid set of tests. 
Manufacturers are responsible for the selection of tests they deem relevant for each device depending on the 
intended device application. As described in the previous section, a risk management process is required by 
Council Directives and the evaluation of biological safety form part of this procedure83. Biological safety 
assessment is thus an essential evaluation that must be performed. Table 1 reports the different topics 
covered by ISO 10993. Among the eighteen parts, five of them involve animal testing. Animal tests are 
performed to assess: skin irritation and intra-cutaneous reactivity (Part 10)84, skin sensitization (Part 10)84, 
systemic toxicity (Part 11)85, genotoxicity, carcinogenicity and reproductive toxicity (Part 3)86, implantation 
(Part 6)87 and haemocompatibility (Part 4)88. A detail description of these tests is provided in section 5 
below.  
 
 
 
 
                                                          
82 Morais J. M. et al., Biomaterials/Tissue Interactions: Possible Solutions to Overcome Foreign Body Response, American 
Association of Pharmaceutical Scientists Journal (2010), Vol. 12(2), 188-196 
83 ISO 10993-1, Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process, 
International Organization for Standardization (2009) 
84 ISO 10993-10, Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitization, International 
Organization for Standardization (2010) 
85 ISO 10993-11, Biological evaluation of medical devices - Part 11: Tests for systemic toxicity, International Organization for 
Standardization (2017) 
86 ISO 10993-3, Biological evaluation of medical devices - Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity, 
International Organization for Standardization (2009) 
87 ISO 10993-6, Biological evaluation of medical devices - Part 6: Tests for local effects after implantation, International 
Organization for Standardization (2016) 
88 ISO 10993-4, Biological evaluation of medical devices - Part 4: Selection of tests for interactions with blood, International 
Organization for Standardization (2017) 
Medical Devices Biological Safety Assessment: Towards Animal-free Testing Nadège Sachot - Augusto Vitale 
 
 104         Derecho Animal. Forum of Animal Law Studies, vol. 10/1           
 
Table 1 Standard ISO 10993 (Biological evaluation of medical devices (Highlighted in grey: standards 
implying animal testing) 
 
ISO 10993-1 Part 1: Evaluation and testing within a risk management process 
ISO 10993-2 Part 2: Animal welfare requirements 
ISO 10993-3 Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity 
ISO 10993-4 Part 4: Selection of tests for interactions with blood 
ISO 10993-5 Part 5: Tests for in vitro cytotoxicity 
ISO 10993-6 Part 6: Tests for local effects after implantation 
ISO 10993-7 Part 7: Ethylene oxide sterilization residuals 
ISO 10993-8 Withdrawn 
ISO 10993-9 Part 9: Framework for identification and quantification of potential degradation 
products 
ISO 10993-10 Part 10: Tests for irritation and skin sensitization 
ISO 10993-11 Part 11: Tests for systemic toxicity 
ISO 10993-12 Part 12: Sample preparation and reference materials 
ISO 10993-13 Part 13: Identification and quantification of degradation products from polymeric 
medical devices 
ISO 10993-14 Part 14: Identification and quantification of degradation products from ceramics 
ISO 10993-15 Part 15: Identification and quantification of degradation products from metals and 
alloys 
ISO 10993-16 Part 16: Toxicokinetic study design for degradation products and leachables 
ISO 10993-17 Part 17: Establishment of allowable limits for leachable substances 
ISO 10993-18 Part 18: Chemical characterization of materials 
 
4.3  Council Directive on the protection of animals used for scientific purposes 
 
The use of animals for scientific purposes such as for the tests involved in the biological evaluation of 
medical devices is regulated in the EU by the Directive 2010/63/EU89. This Directive has two main 
objectives. First, it aims to harmonise the legislation related to animal research throughout the EU Member 
States and, second, to regulate the use of research animals and improve their protection. This Directive 
applies to live non-human vertebrate animals and cephalopods, and is based on three internationally 
recognized principles: replacement, reduction and refinement (also known as the 3Rs Principle). This 
principle was initially defined in 1959 by W. M. S. Russell and R.L. Burchas90: 
 
• Replacement: “the substitution for conscious living higher animals of insentient material”; in the 
sense that conscious vertebrates could be replaced by plants, microorganisms or endo-parasites91 for 
example. In other words, Russell and Burch considered that sentient animals could be replaced by  
non-sentient materials, being animals or non-animals.  
• Reduction: “reduction in the numbers of animals used to obtain information of a given amount and 
precision”; meaning that the number of animals is reduced while valid scientific data can still be 
acquired.  
• Refinement: “any decrease in the incidence or severity of inhumane procedures applied to those 
animals which still have to be used”; meaning that practices are adjusted to reduce the potential 
suffering, pain and distress caused to animals.  
 
Nowadays, the 3Rs Principle is reflected and formulated in the Article 4 of the Council Directive as 
follow89: 
 
“Member States shall ensure that, wherever possible, a scientifically satisfactory method or testing 
strategy, not entailing the use of live animals, shall be used instead of a procedure. 
                                                          
89 European Commission, Council Directive, Directive 2010/63/EU on the protection of animals used for scientific purposes, 
Official Journal of the European Union (2010), L 276/33 
90 Tannenbaum J. and Taylor Bennett B. Russell and Burch’s 3Rs Then and Now: The Need for Clarity in Definition and Purpose, 
Journal of the American Association for Laboratory Animal Science (2015), Vol. 54(2), 120-132 
91 At this time, the nervous and sensory systems of endo-parasites were considered atrophied 
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Member States shall ensure that the number of animals used in projects is reduced to a minimum 
without compromising the objectives of the project. 
Member States shall ensure refinement of breeding, accommodation and care, and of methods used 
in procedures, eliminating or reducing to the minimum any possible pain, suffering, distress or 
lasting harm to the animals” 
 
Following these principles, essential requirements were laid down. These requirements cover a broad range 
of aspects: 
 
• The use of certain animals in scientific procedures: provisions on endangered species, non-human 
primates, stray and feral animals from domestic species, animals from the wild, and animals bred for 
use in procedures. 
• The scientific procedures used: anaesthesia, reuse, classification of severity of procedure, end of 
procedure, killing methods… 
• The authorisations required to perform a procedure: competent professionals (breeders, suppliers, 
veterinarians…), adequate installations and equipment availability of animal records… 
• The project: application for project, evaluation of project, granting of project… 
• The potential use of alternatives methods to animal models: acceptance of data from other Members 
States to avoid duplication, relevance and suitability of alternative approaches, establishment of 
national committees for the protection of animals…  
 
The legislative framework of Council Directive 2010/63/EU provides thus best practice guidance for 
individuals involved in animal testing. ISO 10993 (Part 2: animal welfare requirements)92 is closely related 
to this Directive since the animal tests described in ISO 10993 enter the scope of this Directive. 
 
5. Animal testing and medical devices biological evaluation (toxicological studies)  
 
Animal testing for the biological evaluation of medical devices is mostly used to assess the 
toxicological potential of devices, i.e. the adverse events they may cause to organisms93. Of course, raw 
materials selected to design the devices are chosen based on their non-toxicity. Nevertheless, material 
properties may be altered by the device manufacturing process. The addition of a colorant, the use of a 
thermal treatment or the sterilization of the device for example may induce the formation of toxic substances 
which may be released from the device along its application. For this reason, the toxicity of the devices 
must, in any case, be evaluated. This does not mean that animal testing will be systematically conducted. As 
described above, the evaluation is based on a risk assessment procedure94. If enough data are already 
available (clinical data and equivalence to an existing device for example) to perform the toxicological 
assessment and ensure that the device will not harm the patient health, animal testing may not be needed. On 
the contrary, if data are insufficient, animal testing may be performed. The nature and extent of the testing is 
then determined depending on the device final use (type and duration of contact with the body)95. The 
following section reviews the animal testing listed in ISO 10993 that may be conducted to evaluate the 
biological safety of medical devices. 
 
5.1.  Skin irritation and intra-cutaneous reactivity 
 
Skin irritation test is a test performed to evaluate the potential of a material to induce reversible skin 
damages in an animal model, i.e. an inflammatory response caused by the immune system of the skin after 
being in contact with a substance. Albino rabbits are the standard experimental subjects for this test84,96. This 
test consists in shaving the back of the rabbits and applying to their skin a test substance. The test substance 
may be a liquid, a solid or an extract in the case of some medical devices (extraction in polar solvent such as 
water, saline solution and cell culture medium, or non-polar solvent such as cottonseed oil, olive oil, sesame 
                                                          
92 ISO 10993-2, Biological evaluation of medical devices - Part 2: Animal welfare requirements, Official Journal of the European 
Union (2006) 
93 Parasuraman S. Toxicological Screening, Journal of Pharmacology and Pharmacotherapeutics (2011), Vol. 2(2), 74-79 
94 Myers D. K. et al., From In Vivo to In Vitro: The Medical Device Testing Paradigm Shift, ALTEX (2017), Vol. 34(4), 479-500 
95 Schuh J. C. L. Medical Device Regulations and Testing for Toxicologic Pathologists, Toxicologic Pathology (2008), Vol. 36, 63-
69 
96 Lee M. et al., Alternatives to In Vivo Draize Rabbit Eye and Skin Irritation Tests with a Focus on 3D Reconstructed Human 
Cornea-Like Epithelium and Epidermis Models, Toxicological Research (2017), Vol. 33(3), 191-203 
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oil). Gauze patches, preliminary soaked in the test substance, are placed on defined dorsal sites of the rabbits 
(Figure 9). Control patches (commonly saturated with the liquid used for extraction) are also applied on the 
rabbits back in order to be able to distinguish, at the end of the assay, between the effect of the extract 
vehicle and the one of the material itself. The patches are maintained on the rabbits back for at least 4h. 
After this time, the patches are removed. The sites of application are then marked with permanent ink and 
finally washed with water. The skin reaction is evaluated by visual observation after approximately 1, 24, 48 
and 72h for a single-exposure test. In the case of a repeated-exposure test, the skin reaction is recorded after 
1h removal of the patches and new patches are immediately deposited on the same locations of the previous 
patches.  After the last exposure, the visual inspections are made at the same duration intervals as for the 
single-exposure test.  Skin reaction is evaluated by the observation of signs of erythema and oedema and is 
scored depending on the severity and reversibility of the irritation. The grading of the irritation reaction is 
provided in ISO 10993-1084 and enables the calculation of a so called primary or cumulative irritation index 
(single-exposure test and repeated-exposure test respectively). This index is ultimately used to determine the 
classification of the test substance as negligible, slight, moderate or severe irritant.  
 
 
Figure 9 Location of the test/control patches sites applied on a rabbit back for skin irritation test. 
(Sources: picture of the rabbit: https://blogs.rspca.org.uk/insights/2012/04/03/lab-animal-law-
government-actions-will-speak-louder-than-words/#.WuQnaX9CSUk; scheme: adapted from ISO 10993-
10) 
 
Intra-cutaneous reactivity test is also a test aiming to assess the irritation potential of a medical device 
but, unlike the skin irritation test described above, the test substance is injected intra-dermally84. Since the 
test substance is directly placed into the skin and not simply contacting it, this test is considered much more 
aggressive. This test is used for implant medical devices and is often performed with extracts of the medical 
devices97. The basic principles of this test are quite similar to the ones of the skin irritation test: the rabbit 
back is shaved, the test substance is applied (in this case, five injections of control and test substance (Figure 
10)), the reactivity of the skin is observed by visual observation, and the irritation grade is determined. As 
for the skin irritation test, the skin reaction is also examined based on signs of erythema and oedema and is 
scored depending on the severity and reversibility of the irritation. Medical devices are not considered 
irritant as long as the final scoring is 1.0 or less.  
                                                          
97 Simeonova R. and Danchev N. Assessment of surgical sutures Polymed® by intracutaneous irritation test in rabbits, 
Interdisciplinary Toxicology (2013), Vol. 6(2), 99–102 
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Figure 10 Location of the test/control injection sites applied on a rabbit back for intra-cutaneous 
reactivity test. 
(Sources: adapted from ISO 10993-10) 
 
5.2.  Skin sensitization 
 
Skin sensitization test is a test conducted to evaluate the presence of an allergen in a test substance. 
Foreign agents such as allergens that come into contact with skin may cause a hypersensitivity reaction due 
to the biological response of the body’s immune system98. It is usually characterized by redness and 
swelling of the allergen-contacted skin. Three tests may be used to evaluate skin sensitization84: 
 
• The closed-patch test; using guinea pigs(referred as Buehler test) 
• The maximization test; using guinea pigs (referred as GPMT) 
• The local lymph node assay; using mice (referred as LLNA) 
 
Sensitization develops in two phases. First, when skin is exposed by contact to an allergen, a 
specialized primary immune response is provoked98. This phase, called the induction phase, primes and 
sensitizes the immune system and usually does not induce clinical symptoms. The second phase, named 
challenge phase, is depicted as the triggering of the allergic response after re-exposure to the allergen and is 
associated to the development of clinical symptoms (i.e. skin reaction). It is thus necessary to first sensitise 
and then challenge the immune system of the animals in the Buehler test84.99. To do so, the back of the 
guinea pigs are shaved and patches saturated with the test substance (or liquid of the extracts for the control 
guinea pigs) are placed on the shaved area. The patches are removed after 6h. This procedure is performed 
three days a week during three weeks. After 14d, the sensitised animals can be challenged. A skin area 
which was not tested yet (commonly the flank) is shaved and test substance-soaked patches are applied to 
this area. As for the induction phase, the patches are removed after 6h. The guinea pigs are shaved again 
after 24h following the last challenge phase, and 2h after the shaving, the visual observation is made. The 
grading of the skin reaction is assigned based on the Magnusson and Kligman scale provided in ISO 10993-
1084. The grading is evaluated again after 24h after the first observation. The test substance is considered 
sensitizer if the grade of the test animals exceed the most severe reaction of the control animals.  
The guinea pig maximization test (GPMT) is considered more sensitive than the Buehler test99. The 
GPMT relies also on an induction phase and a challenge phase84,99. Nevertheless, while the induction phase 
of the Buehler test implies only one step (induction by topical application), the induction phase in the GPMT 
implies induction by intradermal injections and topical application.  The substances injected are: Freund's 
complete adjuvant mixed with the liquid used for the extract, the extract, and Freund's complete adjuvant 
mixed with the extract. Freund's complete adjuvant is used to enhance the immune reaction of the guinea 
pig. In the case of control animals, a blank is used instead of the test substance. The intradermal injections 
are performed in the previously shaved nuchal area of the guinea pigs. Figure 11 shows the distributions of 
                                                          
98 Kimber I. et al., Skin sensitization testing in potency and risk assessment, Toxicological Sciences (2001), Vol. 59, 198-208 
99 Frankild S. et al., Comparison of the Sensitivities of the Buehler Test and the Guinea Pig Maximization Test for Predictive 
Testing of Contact Allergy, ActaDermato-Venereologica  (2000), Vol. 80, 256-262 
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the injections. After 7d, the injection sites are covered by a patch saturated with the test substance. The 
patch is removed after 48h. Challenge phase takes place after 14d following the end of the induction phase. 
Skin areas which were not tested yet (commonly the flank) are shaved and patches soaked either in test 
substance or blank patches are applied to these areas. The patches are removed after 24h, and grading of the 
skin reaction and possible classification of test substance as sensitizer are determined as for the Buehler test. 
 
 
Figure 11 Location of the intradermal injection sites on a guinea pig nape for GMPT skin 
sensitization. 
(Sources: picture of the guinea pig: https://www.criver.com/products-services/find-model/hartley-guinea-
pig?region=27; scheme: adapted from ISO 10993-10) 
 
The local lymph node assay (LLNA) is nowadays the preferred test to evaluate skin sensitization. A 
characteristic of skin sensitization response during the induction phase is the proliferation of allergen-
responsive lymphocytes in the draining lymph nodes of the allergen-contacted tissue98. The quantification of 
the lymphocytes is thus a direct approach to evaluate the degree of allergenic reaction100. The test substance 
(or blank for control) is applied to the dorsum of the mice ears. A fluorescent or radioactive marker is 
administered intravenously through the mice tails after 72h following the last application. This marker 
enables the labelling of the proliferating lymphocytes in the lymph nodes. Five hours after this injection, the 
mice are euthanized and their auricular nodes are removed. Cells from the nodes are obtained by pressing 
the lymph nodes through a mesh and are suspended in a solvent that is either supplemented with a 
scintillation fluid to measure the fluorescence or directly transferred to a gamma counter to measure 
radioactivity. The levels of fluorescence or radioactivity related to the test substance and the blank are used 
to calculate the so-called Stimulation Index. To be defined as sensitizer, the substance must lead to a 
stimulation index equal or superior to three.  
 
5.3.  Systemic toxicity 
 
Systemic toxicity is defined in ISO 10993-11 as the “toxicity that is not limited to adverse effects at 
the site of contact between the body and the device”85. Systemic toxicity is sub-classified in four types of 
toxicity: acute, subacute, subchronic and chronic. Acute toxicity usually deals with the adverse reactions 
that occur rapidly (typically within three days) after a single or limited exposure to a substance for 24h. 
Subacute, subchronic or chronic toxicity is rather related to the adverse reactions from repeated or 
continuous exposure for prolonged timeframes (subacute: exposure between 24h and 28d, subchronic: 
exposure for a part of the lifespan, chronic: for a major part of the lifespan). There is no preferred animal 
species to assess systemic toxicity. Mice, rats, rabbits, dogs or monkeys for example may be used for this 
testing. However, the choice of the animal species may be directed by different factors such as the 
administration route of the test substance during the study and the duration of the study (evaluation of acute, 
subacute, subchronic or chronic toxicity). When investigating systemic toxicity, the test substance is 
administrated through dermal, intradermal, intramuscular, intravenous, oral, subcutaneous, implantation, 
inhalation or intraperitoneal routes. The administration must simulate, if possible, the clinical use of the 
investigated medical device. After the administration(s), the animals are regularly observed at a frequency 
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that is defined depending on the study (e.g. nature, severity, rate of onset of toxic reactions). Clinical 
observations such as respiratory deficiencies, eye lacrimation, excessive salivation or diarrhoea, as well as 
body weight changes and cases of morbidity and mortality are recorded. If relevant, clinical pathology 
(haematology, clinical biochemical analysis, urinalysis …) may be also monitored along the study. After 
euthanasia, the gross necropsy (examination of orifices, cavities and their content) of the animals may be 
additionally assessed and followed by the weighing of some selected organs and histopathological studies. 
Results obtained are evaluated statistically based on the observations and findings made along the study 
(type of lesions, number of animal suffering from each lesion, mortality, behavioural abnormalities 
…)101,102. Finally, the adverse effects observed are discussed in terms of biological relevance and relevance 
to human beings.  
 
5.4.  Genotoxicity, carcinogenicity and reproductive toxicity 
 
A genotoxic substance is a substance that induces gene, DNA and/or chromosome structure damages. 
The genotoxicity of a substance is first investigated by performing a set of in vitro studies. Bacteria are used 
to assess gene mutations, mammalian cells to assess chromosomal damages and mouse lymphoma cells to 
assess the development of cell colonies. In vivo testing may be conducted only if justified, i.e. for example 
when other relevant factors to genotoxicity are not covered by the in vitro testing. In vivo tests suggested by 
ISO 10993-386 all involve rodents: the mammalian in vivo micronucleus test, the chromosome aberrations 
test and the transgenic mutagenicity test (guidelines OECD 474, 475 and 488 respectively)103,104,105. The 
animals used for testing are exposed to the test substance and then euthanized to investigate different 
characteristics. The first test consists in the analysis of red blood cells of treated animals and the presence of 
micronuclei in those cells. The second test is based on the analysis of the metaphase (a stage of cell mitosis) 
of bone marrow cells and the evaluation of chromosome structure and morphology (addition of genetic 
material, deletion of a part of a chromosome, loss of one chromosome arm …). The third test relies on the 
measurement of mutations (mutant frequency) in a specific gene. All these results are indicators of genome 
damages that may have been induced by the test substance. 
A carcinogenic substance is a substance that induces cancer. Cancers are characterized by the 
uncontrolled multiplication of abnormal cells. They may form clusters (malignant tumours), invade nearby 
tissues and spread to other tissues by means of the bloodstream and lymphatic system. Carcinogenicity test 
may not be conducted if the test substance is not defined as genotoxic or is not structurally related to 
carcinogens for example. If testing is deemed necessary, carcinogenicity must be evaluated using rodents 
(usually rats) and following the guidelines OECD 451 and 45386,106,107. Similarly to systemic toxicity 
studies, after exposure to the test substance, animal body weight and clinical observations must be recorded. 
Haematology, clinical biochemical analysis and urinalysis may be also of relevance for carcinogenicity 
studies. After euthanasia, a gross necropsy is performed and tissues and organs are used for 
histopathological examination. The results are analysed in terms of tumour incidence (compared to control 
animals), analysis (benign or malignant tumour) and invasiveness (affected surrounding tissues, metastasis).  
A reproductive toxic substance is a substance that alters the reproductive system. Such substances can 
for example negatively impact fertility, hormonal cycle, embryo development and intellectual development. 
The assessment of reproductive toxicity is conducted only if the substance may pose a concrete risk for 
reproduction. If the testing is judged required, testing must be conducted following guideline OECD 
42186,108. This testing is performed with male and female rats. It consists in exposing the animals to the test 
substance (often by oral administration) and evaluating various aspects of the processes driving 
reproduction. As for the other toxicity studies, the body weight changes and clinical observations are 
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recorded. However, specific parameters are additionally assessed: oestrous cycle monitoring, thyroid 
hormone measurement, offspring parameters observation. Gross necropsy and histopathology are also part 
of the analysis. The observations and findings obtained from the study enables the preliminary evaluation of 
the reproductive toxicity potency of the test substance. If further data are required, specific tests may be 
performed in accordance with guidelines OECD 414, 415 and 416109,110,111. These tests describe the prenatal 
development toxicity study, and one-generation and two-generation reproduction toxicity studies.  
Reproductive toxicity studies cover thus the overall mechanisms implied in reproduction, from fertility to 
postnatal development, including parturition and lactation.  
 
5.5.  Implantation 
 
Implantation is performed to evaluate the interaction between a material and a tissue by analysing the 
biological response of the host tissue and the retrieved material. Depending on the duration of the planned 
study (in accordance with the clinical exposure of the medical device), different animal models may be used. 
For short-term implantation, rodents and rabbits are recommended. For long-term implantation, rodents and 
rabbits may be used as well but dogs, sheep, goats, and pigs are usually preferred.  The implantation site is 
defined based on the clinical use of the medical device. ISO 10993-6 describes procedures for implantation 
in subcutaneous tissue, in muscle, in bone and in brain tissue87. As example, a permanent hip implant might 
rather be tested in the hip of a goat (implantation in bone), while a fast-degrading wound dressing patch 
might rather be implanted subcutaneously in a rat.  The evaluation of the biological response is done based 
on the engendered macroscopic, microscopic and histopathological responses. Typical local biological 
effects that are evaluated after implantation include capsule formation, inflammatory response, necrosis, 
vascularization and fatty infiltration87,112.Other effects such as fragmentation or degradation of the material, 
potential tissue ingrowth on the material and formation of new tissue around the material are also taken into 
account. Implantation is thus used when the local pathological effects due to a medical device need to be 
determined.  
 
5.6.  Haemocompatibility 
 
Haemocompatibility testing aims to evaluate the adverse reactions when a material comes into contact 
with blood. Haemocompatibility is assessed for devices having a direct or indirect contact with blood. 
Examples of devices tested for haemocompatibility are cannulae, catheters, haemodialysis devices, artificial 
heart, heart valves prosthesis and stents. The testing is mainly conducted in vitro, but animal testing may, in 
some cases (e.g. implants), be needed to simulate as closely as possible the conditions of clinical use. The 
interactions of devices with blood are commonly assessed by evaluating haemolysis, thrombosis, 
coagulation, platelets and haematology88,113. The selection of the tests, as well as the animal model (pigs, 
dogs, sheep …), depends on the category to which the medical device belongs. On the other hand, 
depending on what is aimed to be assessed, different techniques may be used for investigation: imaging of 
the device to assess thrombosis, measurement of blood plasma level to evaluate coagulation, differential 
blood cell counting to determine blood cell physical damages… Since a variety of tests and evaluation 
methods are available for haemocompatibility testing, the selected investigation procedures have to be 
carefully selected and defined for each specific device to be assessed88.  
 
6. General limitations of animal testing and specific limitations of animal testing relevant to 
toxicological studies 
 
Toxicological studies constitute the basis of medical devices safety assessment and guide the 
evaluation of medical devices biocompatibility within a regulatory framework. Even though in vitro testing 
is part of the evaluation, the prediction of the potential effects of a medical device on human health is 
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primarily based on the results of in vivo testing114. From a general point of view, the legitimacy and 
feasibility of animal experimentation for toxicological studies is currently challenged by issues that are 
common to numerous animal testing procedures, i.e. ethical and experiment methodological concerns114,115. 
From a more specific point of view, some aspects relate more specifically to toxicology, as for instance the 
high cost of toxicological tests and the relevance and usefulness of animal responses in reflecting the 
biological processes taking place in humans116,117. The following section discusses these general and specific 
limitations of animal testing relevant to toxicological studies.  
  
6.1.  Ethical considerations (general limitation)  
 
As described in the introduction of sections 2 and 3, animals have been largely used over the past for 
research purposes. According to Martin L. Stephens and Nina S. Mak, the extensive use of animal for 
toxicological studies relied on “the rise of animal (mostly rodent) breeding for science in general, the virtual 
absence of more sophisticated ways of assessing toxicity, and the low status of animals in society”118. In the 
last decades, the scientific view on the quasi systematic use of animals for testing has evolved and new ways 
of thinking have emerged. Nowadays, the scientific community is divided based on their approach to animal 
testing as follow: 1. those who support animal testing, 2. those opposed, and 3. those described as the 
“trouble-middle” i.e. those concerned about the interests of both humans and animals115. The first part 
claims that there is no ethical concern of using animals as experimental subjects and that the acquisition of 
scientific knowledge prevails. The second part advocates that animals have inherent values and that they 
should not be exploited for research. The last part accepts that animal testing is performed but only in some 
cases which are deemed necessary to contribute to the development of science, and under some specific 
conditions which align with the ethical responsibilities of the scientific community. A conflict exists thus 
between the different contemporary ethical views on that topic, debating on the benefits of animal research 
and the morality of impairing the welfare of laboratory animals and/or killing them119. It should be however 
noted that ethical considerations on that matter does not only rise from scientists but also from the public. 
According to a survey performed in UK in 2016 by IPSOS MORI on the public attitudes to animal research, 
59% of the interrogated citizens declared that they are bothered by the use of animals in research120. Taking 
into account the public opinion, values and concerns is essential for the establishment of socially accepted 
scientific practices because modifications or creation of new regulation and policies are often pushed by 
public engagement121,122. The ethical dilemma on the use of animal-based science is thus a contentious 
ethical topic which does not only affect the scientific community but the society as a whole. 
 
6.2.  Methodological issues (general limitation)  
 
Another issue with animal testing is that the experiments are often poorly designed, analysed and 
reported, and conducted with lack of methodological quality114,123. This may introduce bias in the studies, 
i.e. “a systematic error, or deviation from the truth, in the results of a study or the conclusions drawn from 
it”124. Such bias may affect the reliability and reproducibility of the experimental findings and contribute to 
the failure of animal-based research to replicate in humans124,125,126. Types of bias include mainly selection, 
performance, detection, attrition and reporting bias127.  Examples of such bias are the lack of randomization 
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of animals assigned to the trial, inappropriate statistical considerations (sample size) to obtain robust data 
and “non-blinding” of the outcome investigators123,127,128. A concrete example of a bias detected in 
toxicological studies is the dose of test substance that is administered to the animal. The administered dose 
is commonly the maximal dose that is tolerated by the animal and is usually significantly higher than the 
dose intended for humans117. Combined to the complexity of dose-response relationship underlying 
toxicology, this makes the extrapolation of the obtained results highly uncertain129. Another important factor 
that can be too often underestimated by scientists is the conditions of animal husbandry. An article written 
by Nold and co-authors reported that rodents feeding diet types influenced the responses of animals to test 
substances by altering sensitivity and tissue vulnerability130. Diets have for example a direct impact on the 
tolerance of animals to carcinogens and this may lead to the drawing of flawed conclusions. The ultimate 
risk of biased or imprecise results is that clinical trials may be conducted based on unreliable data and this 
may pose a concrete risk for patients123. This additionally raises another concern which is the conduct of 
animal testing that may not be needed if the results become inconclusive123. There is therefore an undeniable 
need in improving the quality of scientific practices and methodologies currently used within animal 
experimentation in order to achieve more beneficial animal testing123,124,131.  
 
6.3.  Correlation of toxicological studies between animal models and humans (specific limitation) 
 
The use of animal models, along with their outcome, is nowadays a pivotal concept used to bridge the 
gap between preclinical and clinical research. Animal testing is described by some scientists as necessary 
because it is the only way to assess the interactions of a substance or a material with a living organism. This 
part of the scientific community considers that the results obtained on animals are in most cases relevant for 
extrapolation to humans and that animal testing contributes to ensure human health and safety125,132. This 
idea is based especially on the claim that humans and animals share close similarities133, i.e. that they are 
biologically and genetically similar6,134. However, this is not something that has to be taken for granted. As a 
matter of fact, various studies point out that animal models can fail in predicting suitably human 
responses133. The main question related to prediction is to what extent are animal models effectively 
reflecting these responses. Even though similarities between humans and non-human animal species exist, 
very small differences may lead to significant different biological mechanisms (e.g. cellular functions, 
cellular pathways…), and consequently different reactions133. It has been shown for instance that substances 
classified as teratogens for humans were not necessary teratogenic for non-human primates, and this despite 
their close phylogenetic relationship114. A review written by Bailey and his colleagues reported indeed that 
when some known human teratogens were tested on primates, only half of them had a teratogenic effect on 
one or more primate species135. On the other hand, although rodents are also genetically very close to 
humans (see section 2), the prediction based on rodent models does not seem to do much better136. A 
popular study performed by Olson et al. showed that only 43% of the toxic effects observed in humans were 
correctly predicted by tests in rodents, and that among the evaluated tests, cutaneous toxicity exhibited the 
least concordance between rodents and human toxicity137. The described studies demonstrate hence that 
animals are not always effective models to predict the toxicological effects occurring in humans. 
Extrapolating the biological responses of a species to another species is in fact particularly delicate and may 
sometimes even be poorly reliable. Nevertheless, this issue persists when extrapolating data within intra-
species138. Indeed, the use of animals from a same species but from different strains may also lead to 
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different results and conclusions. Not only the animal models itself needs to be carefully selected but also 
the animals to be used within this model131,139,. One of the commonly accepted explanations for the 
described discrepancies is that each species, and even each individual, has specific uptake and metabolism 
patterns117,123. This relies on the complexity and fine nuances of biological systems which result mainly from 
the mechanisms and outcome of an evolutionary history125,132,140. Evolutionary adaptations have induced 
over time gene mutations and changes in gene regulation and expression, modifying thus the initial 
conditions. As a consequence, a characteristic manifested in two different lineages does not necessarily 
correlate with the same mechanisms of this characteristic; and this is also valid within the same 
species133,140. The intrinsic complexity of biological systems constitutes moreover an obstacle to the 
prediction principle because complex systems have specific properties and it is therefore irrelevant to assess 
them as if they were simple systems. Justifications for this argumentation was detailed in an article written 
by Greek and his co-authors  in which they described that “complex systems are more than the sum of their 
parts, thus reductionism will yield an incomplete analysis of a complex system […]; complex systems 
exhibit emergence, meaning that new properties of a complex system arise from the interactions of the parts 
[…]; complex systems are resistant to changes and exhibit redundancy in their components; complex 
systems exhibit self-organization; complex systems demonstrate responses to perturbations that are 
nonlinear” and “complex systems are very dependent upon initial conditions (for example, genetic make-
up)” (non-exhaustive list)125. Those considerations complicate thus considerably the extrapolation between 
complex systems. Therefore, particular cautions shall always be taken when using animal models for 
predicting the responses in humans, and awareness shall be raised that straightforward extrapolation may 
cause misleading and false interpretation141. 
 
6.4.  Economic cost of toxicological studies (specific limitations) 
 
A non-negligible aspect of animal testing is the economic cost of such practice. Fleischer M. reported 
in 2007 the average prices of some toxicological tests conducted within the EU and Switzerland. Some of 
the reported tests related to the assessment of medical device safety. The prices for a skin irritation test, for a 
skin sensitization test (LLNA), for an acute toxicity test (inhalation, rats) and for a carcinogenicity test (rats) 
for example were evaluated to 1’645€, 3’959€, 11’734€ and 780’357€ respectively142. The correlation of 
these prices to the total test cost per year and per test type is particularly difficult to establish because, unlike 
the number of animals used for research and scientific purposes2, the number of test procedures is not yet 
officially available143. However, in 2014, a group of researchers tried to approximate the trend for some of 
the EU countries144. They reported for example 7’877 procedures for skin sensitization within Denmark, 
Spain, UK, Poland, Slovakia and Hungary. Taking into account Fleischer’s prices and considering that these 
prices did not increase between 2007 and 2014 (which is quite unlikely), more than 31 million euros would 
have been used for skin sensitization testing; and this considering only six EU countries (over 28 
countries145). This simple estimation obviously does not aim to evaluate the exact cost of some particular 
animal tests but to raise awareness on the significant amount of money that is potentially consumed for such 
testing. For a better accuracy, more recent statistics as well as further factors such as the cost of employment 
of qualified staff and development of appropriate installations would need to be additionally considered116. It 
is nevertheless clear that animal testing represents a significant financial investment for numerous 
institutions and industrials; especially when such testing is pushed by regulatory requirements146 (see section 
4).  
 
7. Alternatives to animal testing used for toxicological studies 
                                                                                                                                                                                                
Reports (2015), Vol. 3, 219–223 
139 Festing M. F. W. Inbred Strains Should Replace Outbred Stocks in Toxicology, Safety Testing, and Drug Development, 
Toxicologic Pathology (2010), Vol. 38, 681-690 
140  Shanks N. et al., Are animal models predictive for humans? Philosophy, Ethics, and Humanities in Medicine (2009), Vol. 4(2), 
1-20 
141 Garner J. P et al., Introducing Therioepistemology: the study of how knowledge is gained from animal research, LabAnimal 
(2017), Vol. 46(4), 103-113 
142 Fleischer M. Testing Costs and Testing Capacity According to the  REACH Requirements – Results of a Survey of Independent 
and Corporate GLP Laboratories in the EU and Switzerland, Journal of Business Chemistry (2007), Vol. 4(3), 96-114 
143 The next complete report on the use of animals in the Member States (reporting the number of procedures) will be published by 
the European Commission in 2019 (http://ec.europa.eu/environment/chemicals/lab_animals/legal_en.htm) 
144 Taylor K. and Rego L. EU statistics on animal experiments for 2014, ALTEX (2016) Vol. 33(4), 465-468 
145 European Union, The 28 member countries of the EU, https://europa.eu/european-union/about-eu/countries_en (Wedpage 
accessed on 31 May 2018) 
146 Bottini A. A. and Hartung T. Food for Thought … on the Economics of Animal Testing, Altex (2009), 26, 1/09 
Medical Devices Biological Safety Assessment: Towards Animal-free Testing Nadège Sachot - Augusto Vitale 
 
 114         Derecho Animal. Forum of Animal Law Studies, vol. 10/1           
 
 
The traditional approaches used for toxicity evaluation, including the assessment of medical device 
safety, are nowadays facing scientific, ethical and economical hurdles. These hurdles are some of the main 
drivers calling for the use of alternatives to animal testing147. The development of non-animal technologies 
that are viable for toxicological studies has thus become a strategic key objective. Scientists from multi-
disciplinary fields, e.g. biologists, chemists, physicians and clinicians, are currently applying the best of the 
available scientific and technological knowledge to develop such alternatives. The section hereinafter 
reviews the most promising approaches being developed within life science engineering and biomedical 
research to move away from animal testing. This review is limited to methods potentially interesting for the 
assessment of medical device safety.  
  
7.1.  In vitro and ex vivo human 3D skin models 
 
Human skin is, as the skin of other mammals, composed of two primary layers: the epidermis and the 
dermis (Figure 12). The epidermis is mainly constituted by keratinocytes and is covered by a thin superficial 
layer of lipids and corneocytes that is named stratum corneum148. The epidermis and the stratum corneum 
play an important role for the barrier function of the skin by protecting the body from the external world (i.e. 
pathogens such as bacteria and viruses, environmental damages such as ultra violet radiation and harmful 
materials etc.) and by controlling the water and electrolytes permeability148. The dermis, beneath the 
epidermis, is constituted by an extracellular matrix (mainly collagen) in which fibroblasts are embedded149. 
It provides the elasticity and stress of the skin.  
 
 
Figure 12 Histological cross section of in vivo human skin. 
(Source: adapted from: De Wever B. et al. Overview of human three-dimensional (3D) skin models used for 
dermal toxicity assessment (Part 1), Household and Personal Care Today (2013), Vol. 8(1), 18-22) 
 
In vitro human skin models are engineered skin constructs consisting of a lattice that contains human 
epidermal keratinocytes and/or dermal fibroblasts (mono or co-culture) and that intends to reproduce the 
skin structure149,150. One of the reasons for the development of such constructs is the possibility to assess for 
example cutaneous toxicity without involving animals. Various types of in vitro skin models are currently 
available on the market (SkinEthic, EST1000®, EpiCS®, Phenion®, LabcyteTM, Stratatest®…) but the most 
well-known (first ones developed) are EpiSkinTM (L’oréal, France) and EpiDermTM (MatTek Corporation, 
USA)149,150. EpiSkinTM is composed of human keratinocytes forming a multilayer differentiated epidermis on 
a collagen matrix. EpiDermTM is constructed on the same principle but keratinocytes are cultured on a 
polycarbonate membrane instead of collagen. Both models reproduce many of the important features 
exhibited by human epidermis (structure, function and expression of markers of epidermal differentiation) 
and are therefore considered morphologically relevant to assess cutaneous toxicity such as irritation (Figure 
13)150,151. Results obtained on reconstructed skin have been demonstrated to be suitable to reproduce the 
typical tissue response of human skin150. Moreover, they represent a more predictive and ethical approach 
                                                          
147 Burden N. et al., Testing Chemical Safety: What Is Needed to Ensure the Widespread Application of Non-animal Approaches?, 
PLOS Biology (2015), Vol. 13(5), e1002156. 
148 Lee S. H. et al., An Update of the Defensive Barrier Function of Skin, Yonsei Medical Journal (2006), Vol. 47(3), 293-306 
149 De Wever B. et al,. Overview of human three-dimensional (3D) skin models used for dermal toxicity assessment (Part 1), 
Household and Personal Care Today (2013), Vol. 8(1), 18-22 
150 De Wever B. et al., Human Skin Models for Research Applications in Pharmacology and Toxicology: Introducing NativeSkin®, 
the ‘‘Missing Link’’ Bridging Cell Culture and/or Reconstructed Skin Models and Human Clinical Testing, Applied in vitro 
Toxicology (2015), Vol. 1(1), 26-32 
151 Boelsma E. et al., Characterization and Comparison of Reconstructed Skin Models: Morphological and Immunohistochemical 
Evaluation, Acta Dermato-Venereologica (2000), Vol. 80, 82-88 
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than animal testing152. Continuous improvement of in vitro skin models is currently being conducted for 
applications within diverse dermal toxicity tests, including skin irritation, skin sensitization and 
genotoxicity149,150,152. 
 
 
Figure 13 Histological cross section of a) in vivo human skin, b) EpiSkinTM and c) EpiDermTM showing 
the similar architecture of natural and engineered skin constructs. 
(Source: adapted from http://iivs.org/testing-services/assays/dermal/irritation-screening/, Webpage 
accessed on 4 June 2018) 
 
Another approach which has great potential for skin toxicity evaluation is testing on ex vivo human 
skin. Ex vivo human skin is an explant harvested from a donor and cultured in laboratory conditions. Up to 
now, the use of such skin was limited due to the difficulties in maintaining physiological biology of skin, its 
barrier function and its metabolism for a defined culture duration150,153. A novel model recently developed, 
NativeSkin®, seems to overcome these drawbacks (Figure 14)150. It is presented as the model of choice to 
predict more accurately cutaneous effects prior to final clinical evaluation in humans because it 
encompasses and preserves all the essential characteristics of natural skin, i.e cell population diversity, 
tissue viability, structure, metabolism and cutaneous barrier properties. This skin culture offers promising 
testing perspectives but further development is still needed before reaching scientific acceptance.  
 
 
Figure 14 Histological cross section of a) in vivo human skin and b) NativeSkin® showing the similar 
architecture of natural and engineered skin constructs (after 7 days of ex vivo culture). 
(Source: De Wever B. et al. Human Skin Models for Research Applications in Pharmacology and 
Toxicology: Introducing NativeSkin®, the ‘‘Missing Link’’ Bridging Cell Culture and/or Reconstructed Skin 
Models and Human Clinical Testing, Applied in vitro Toxicology (2015), Vol. 1(1), 26-32) 
 
7.2.  Organs-on-chips 
 
Organs-on-chips are microfluidic devices developed to culture living cells in continuously perfused 
micro-meter-sized chambers154.  The purpose of these devices is to model physiological functions of tissues 
and organs by summing up “the critical tissue–tissue interfaces, spatiotemporal chemical gradients, and 
dynamic mechanical micro-environments of living organs”155. A variety of tissues and organ systems such 
as liver, kidney, lung and skin can be modelled (Figure 15)155. Micro-physiological systems can be used 
either to assess a single system (e.g. its basic functions and biological responses) or inter-connected multiple 
                                                          
152 Hewitt N.J. et al., Use of Human In Vitro Skin Models for Accurate and Ethical Risk Assessment: Metabolic Considerations, 
Toxicological Sciences (2013), Vol. 133(2) 209–217  
153 Nakamura M. et al., Full-tickness human skin explants for testing the toxicity of topically applied chemicals, Journal of 
Investigative Dermatology (1990), Vol. 95, 325-332 
154 Bhatia S. N. and Ingber D. N. Microfluidic organs-on-chips, Nature Biotechnology (2014), Vol. 32(8), 760-772 
155 Huh D. et al., Micro-engineered physiological biomimicry: Organs-on-Chips, Lab Chip (2012), Vol. 12, 2156–2164 
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systems (e.g. the interactions between the different interfaces)154,155,156. For example, researchers from Korea 
recently created a skin-on-chip model able to simulate skin oedema157; a characteristic of skin irritation 
which is taken into account when evaluating the irritancy potential of a test substance (see section 5). In 
comparison to the in vitro skin models described above, this microfluidic device included a vascular layer 
made of endothelial cells which are involved in the formation of erythema and oedema. The integration of 
this layer into the system was particularly valuable and enabled thereby the investigation of an additional 
skin irritation feature that is not considered with engineered human epidermis. Another group of researchers 
also successfully developed a dynamic multi-organ chip with co-cultures of human artificial liver micro-
tissues and skin biopsies that could be used to assess the systemic toxicity of substances158. Thus, organs-on-
chips offer the great advantage that their design can be tailored and that they can be used to study specific 
biological phenomena such the ones involved in toxicological adverse reactions. Nevertheless, this 
perspective is challenged by the complexity of the human body and organ functions, and the difficulty in 
“integrating multiple organ chips in a physiologically relevant way to model whole human 
physiology”155,156. Therefore, thorough studies still need to be conducted to support the further development 
of this tremendous technology that could ultimately be used to replace animal experiments.  
  
 
Figure 15 Examples of organ-on-chip models. 
(Source: adapted from Huh D. et al., Micro-engineered physiological biomimicry: Organs-on-Chips, Lab 
Chip (2012), Vol. 12, 2156–2164 and Wufuer M. et al., Skin-on-a-chip model simulating inflammation, 
edema and drug-based treatment, Nature - Scientific Reports (2016), Vol. 6, 37471 (1-12)) 
 
7.3.  Stem cells 
 
Stem cells are cells able to generate identical copies of them-selves and to differentiate into multiple 
cell lineage159,160. In vitro differentiation consists in inducing a defined cell phenotype (expression of 
functional characteristics and morphology) from undifferentiated cells by culturing them under specific 
conditions (culture medium supplemented with growth factors/cytokines/extracellular matrix molecules, 
application of physical stimuli …)159,161. Typical examples of somatic cells derived from stem cells are 
hepatocytes, cardiomyocytes, haemocytes, neurons and others (Figure 16)159,160,162. Stem cells are classified 
in two categories: the embryonic stem cells and the adult (also known as postnatal or mesenchymal) stem 
cells. Embryonic stem cells are able to differentiate into most tissues of the organism (pluripotent cells) and 
are isolated from the blastocyst of mammalian embryos160,161. Adult stem cells are able to differentiate only 
into some tissues of the organism (multipotent cells), meaning that they have lower plasticity than 
pluripotent cells, and are isolated from diverse tissues of the body160,161. Embryonic and adult stem cells 
from both humans and animals have been demonstrated to be a valuable tool to assess reproductive toxicity, 
i.e. the effects of substances on fertility, embryo-toxicity/teratogenicity and pre- and postnatal 
development162,163,164. For example, mouse embryonic stem cells can be used to investigate developmental 
                                                          
156 Low L. A. and Tagle D. A. Microphysiological Systems (“Organs-on-Chips”) for Drug Efficacy and Toxicity Testing, Clinical 
and Translational Science (2017), Vol. 10, 237–239 
157 Wufuer M. et al., Skin-on-a-chip model simulating inflammation, edema and drug-based treatment, Nature - Scientific Reports 
(2016), Vol. 6, 37471 (1-12) 
158 Wagner I. et al., A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin 
tissue co-culture, Lab Chip (2013), Vol. 13, 3538-3547 
159 Davila J. C. et al., Use and Application of Stem Cells in Toxicology, Toxicological Sciences (2004), Vol. 79, 214–223  
160 Luttun A. and Verfaillie C. M. A Perspective on Stem Cells as a Tool for In Vitro Testing, ALTEX (2005), Vol. 22 (Special Issue 
2), 388-392 
161 Heng B. C. et al., An overview and synopsis of techniques for directing stem cell differentiation in vitro, Cell and Tissue 
Research (2004), Vol. 315, 291–303 
162 Liebsch M. et al., Alternatives to animal testing: current status and future perspectives, Archives of Toxicology (2011), Vol. 85, 
841–858 
163 Tandon S. and Jyoti S. et al., Embryonic stem cells: An alternative approach to developmental toxicity testing, Journal of 
Pharmacy And Bioallied Sciences (2012), Vol. 4(2), 96–100 
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toxicity. This testing is known as the mouse embryonic stem cell test. It relies on the morphological 
evaluation of growth inhibition of differentiated and undifferentiated cells (fibroblasts and embryonic stem 
cells respectively) and the assessment of differentiation inhibition of the embryonic stem cells into 
cardiomyocytes (cardiac muscle cells)162,163. It enables thereby the study of the early developmental 
processes taking place after fertilization. Human embryonic stem cells can be similarly used for such 
investigation164. On the other hand, human embryonic and adult stem cells can be used to assess the effects 
of substances on a variety of terminally differentiated cells derived from stem cells. Such somatic cells are 
for instance used to assess metabolism toxicology and to carry out screening for teratogens159,164,165,166. Stem 
cell models have been proved to be reliable and to provide consistent data with in vivo results162,164. 
Moreover, stem cells are well established cell lines, have an unlimited proliferation ability and are therefore 
precious experimental ressources162,164. Using stem cells for testing seems thus to be a promising strategy to 
perform toxicity assessment (especially assays related to cytotoxicity, functional toxicity and developmental 
toxicity).  
 
 
Figure 16 Origin of embryonic stem cells (pluripotent stem cells) and adult stem cells (multipotent 
stem cells) and examples of somatic cells derived from them. 
(Source: adapted from Davila J. C. et al., Use and Application of Stem Cells in Toxicology, Toxicological 
Sciences (2004), Vol. 79, 214–223) 
 
7.4.  Omics technologies 
 
Omics technologies encompass the study of gene expression and the cellular constituents controlled 
by the genome (Figure 17). They refer to the “methods of measuring families of cellular molecules such as 
ribonucleic acid (RNA167), proteins168 and intermediary metabolites169”170. Concretely, five research lines 
exist within the field of omics technologies:  
                                                                                                                                                                                                
164 Liu S. et al., Prospects and Frontiers of Stem Cell Toxicology, Stem cells and development (2017), Vol. 26(21), 1528-1539 
165 Braam S. R. et al., Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes, Stem 
Cell Research (2010), Vol. 4, 107–116 
166 Zeng X. et al., An In Vitro Model of Human Dopaminergic Neurons Derived from Embryonic Stem Cells: MPP+ Toxicity and 
GDNF Neuroprotection, Neuro-psychopharmacology (2006), Vol. 31(12), 2708–2715 
167 RNA molecules are molecules that serve as intermediaries on the pathway to proteins.  Messenger RNA (mRNA) is conveying 
genetic information from the cell nucleus to the cytoplasm where the protein synthesis takes place. Alberts B. et al,. Molecular 
Biology of the Cell. 4th edition. New York: Garland Science (2002). From RNA to Protein. 
https://www.ncbi.nlm.nih.gov/books/NBK26829/ (Webpage accessed on 08 June 18) / Berg J. M., Tymoczko J. L., Stryer L. 
Biochemistry. 5th edition. New York: W H Freeman (2002). Chapter 5, DNA, RNA, and the Flow of Genetic Information. 
https://www.ncbi.nlm.nih.gov/books/NBK21171/ (Webpage accessed on 08 June 18) 
168 Proteins are molecules involved in many biochemical processes (development, functioning …) and are vital for living organisms.  
Protein Function, Nature, https://www.nature.com/scitable/topicpage/protein-function-14123348 (Webpage accessed on 08 June 18) 
169 An example of metabolites is cofactors i.e. non-protein compounds that are required for an enzymatic activity. 
van der Knaap J. A. and Verrijzer  C. P. Undercover: gene control by metabolites and metabolic enzymes, Genes & Development, 
Vol. 30, 2345–2369 
170 Aardema M. J. and MacGregor J. T. Toxicology and genetic toxicology in the new era of “toxicogenomics”: impact of “-omics” 
technologies, Mutation Research (2002), Vol. 499, 13–25 
Medical Devices Biological Safety Assessment: Towards Animal-free Testing Nadège Sachot - Augusto Vitale 
 
 118         Derecho Animal. Forum of Animal Law Studies, vol. 10/1           
 
 
• genomics: the “study of the structure, function and expression of all the genes in an organism”171;  
• transcriptomics: the “study of the mRNA (messenger RNA167) within a cell or organism”171; 
• proteomics: the “large-scale study of proteins, including their structure and function within a 
cell/system/organism”171; 
• metabolomics: the “study of global metabolite profiles in a system (cell, tissue or organism) under a 
given set of conditions”171; 
• and epigenomics: the “study of reversible heritable changes in gene function that occur without a 
change in the sequence of nuclear DNA”172. 
 
In toxicology, omics technologies can be used for diverse purposes such as the understanding of the 
mode of action of a toxic substance, the assessment of the genetic variations on toxicological outcomes, the 
prediction of toxic responses, the evaluation of dose-responses relationship, the comparison of toxic 
responses between interspecies; among others170,172. These studies are performed by assessing for example 
molecular structure, cellular mechanisms, cellular functional alterations and/or perturbations, DNA 
damages, cell death, changes in gene/protein expression and others170. For instance, a significant milestone 
in the field was the development of DNA microarrays (also named ‘chips’). Chips enable the monitoring of 
the expression of thousands genes simultaneously and can be used as effective marker of toxicity173,174. 
Omics technologies offer thus the possibility to acquire significant amount of comprehensive data related to 
toxicological hazards170,172,175. They are therefore an extremely valuable approach for the establishment of 
toxicity investigation procedures implied in risk assessment, as the ones relevant for medical devices safety 
evaluation.   
 
 
Figure 17 Biological mechanisms governed by the genome and assessed with omics technologies. 
(Source: https://www.nobelprize.org/educational/medicine/dna/index.html, Webpage accessed on 10 June 
2018) 
 
7.5.  In silico modelling techniques 
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172 Sauer U. G. et al., The challenge of the application of 'omics technologies in chemicals risk assessment: Background and outlook, 
Regulatory Toxicology and Pharmacology (2017), Vol. 91, S14-S26 
173 Nuwaysir E. F. et al., Microarrays and Toxicology: The Advent of Toxicogenomics, Molecular Carcinogenesis (1999), Vol. 24, 
153–159  
174 Afshari C. A. et al., Application of Complementary DNA Microarray Technology to Carcinogen Identification, Toxicology, and 
Drug Safety Evaluation, Cancer Research (1999), Vol. 59, 4759-4760 
175 Buesen R. et al., Applying 'omics technologies in chemicals risk assessment: Report of an ECETOC workshop, Regulatory 
Toxicology and Pharmacology (2017), Vol. 91, 1-11 
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In toxicology, in silico models are models that integrate modern computing and information 
technology with molecular biology to gain understanding on the molecular mechanisms of toxicity176. These 
models can be applied for example to predict the specific organ toxicity properties of a substance176. Various 
types of in silico tools currently exist but the most prominent ones are the quantitative structure-activity 
relationships (QSAR) tool, the modelling tools and the kinetics models of substances177 (Figure 18). The 
first tool, QSAR, relies on the description of chemical substances structures by certain parameters (i.e. 
descriptors) and the use of “a mathematical model that correlates a quantitative measure of chemical 
structure to either a physical property or a biological effect (e.g. toxic outcome)”176,177. The second tool, 
modelling, is rather used to determine the likelihood of a substance to trigger a specific response177. This is 
achieved for example by modelling the fit of a substance into a reactive site of a receptor. This application, 
called receptor modelling, is one of the common uses of this second tool. Finally, the third tool (models of 
kinetics of substances) refers to the absorption, distribution, metabolism and excretion (ADME) of 
substances interacting with living organisms176,177. This tool is based on the physico-chemical properties of 
the assessed test substance and on models of various relevant factors (blood flow, organ characteristics ...). 
According to Hartung T. and Hoffmann S., the added value of in silico technologies is “the objectivity and 
the tools to appraise our toolbox” as well as the possibility “to combine various approaches in more 
intelligent ways than a battery of tests”177. These methods are therefore expected to be furthermore 
developed in the near future with the goal to become relevant and reliable, and ultimately, to replace the 
acquisition of test data such as with animal testing176,178.   
 
 
Figure 18 Types of currently available in silico tools. 
(Source:  Raies A. B. and Bajic V. B. In silico toxicology: computational methods for the prediction of 
chemical toxicity, WIREs Computational Molecular Science (2016), Vol. 6, 147–172) 
 
8. Implementation of animal testing alternatives 
 
Other the past years, more and more attention has been given to the development of alternatives to 
animal testing. As reflected by the examples listed above, promising approaches arose from the intensive 
work of the scientific community.  Apart from this scientific progress, there is however an essential aspect 
of alternatives that needs to be considered when talking about the assessment of medical device safety: the 
regulatory acceptance of newly developed testing methods. The following section describes the most 
important steps required to establish animal testing alternatives within a regulatory framework and discusses 
the potential of such alternatives to support the 3Rs Principle. 
 
8.1.  Test method validation 
 
Test method validation consists in demonstrating “the appropriateness and usefulness of a tool for its 
intended purpose”179. Examples of characteristics that need to be taken into account when conducting 
method validation are accuracy, precision, repeatability, reproducibility, resolution and robustness180. 
Validation is an essential process needed to ensure the fit-for-purpose of the method and to demonstrate its 
                                                          
176 Raunio H. In silico toxicology: non-testing methods, Frontiers in Pharmacology (2011), Vol. 2, Art. 33, 1-8 
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reliability, as well as to satisfy legal requirements179,181.  In fact, the Directive on the protection of animals 
used for scientific purposes (2010/63/EU) expresses the duty of the Commission and the Member States to 
contribute to the validation of alternative approaches89. Moreover, standard ISO 10993-Part 1 on the 
biological evaluation of medical devices requires the use of in vitro testing methods that are validated83. To 
be validated, a method must fulfil various principles and criteria (e.g. definition of goals, independency of 
data collection, performance of the methods…) which achievement and assessment commonly requires 
time182. In addition, validation does not always align with the evolution of current practices (i.e. emerging 
technologies and complex end-points)183. Therefore, strategies are being considered to make the process 
validation more flexible and more efficient (especially costs and time)182,184. One example is the “modular 
approach” of the validation procedure described by Hartung et al. that consists in breaking down the 
validation process in independent modules and defining the information needed to fulfil each module184. 
Another option is the promotion of meetings and workshops gathering the subject matter experts183. 
Although delicate, validation remains an important task. Given that the outcome of the performed tests is 
used to make critical decision on public health and safety, it is clear that validation plays a pivotal role in the 
implementation of animal testing alternatives. 
Among the alternatives reported in the previous section, some of them have been already validated for 
specific applications. This is for example the case of the reconstructed human epidermis test method used to 
evaluate skin irritation. This method, relying on in vitro models such as EpiSkinTM and EpiDermTM, was 
validated by the European Centre for the Validation of Alternative Methods (ECVAM) to assess the skin 
irritancy potential of chemicals94,162,185. Another approach validated by ECVAM is the embryonic stem cell 
test. The test was validated based on its ability to differentiate between levels of embryo-toxicity (strong to 
non-toxicity) caused by chemicals162,186. However, in vitro skin irritation and stem cell testing alternatives 
have not been validated yet for the assessment of medical device safety. Though, some recent studies show 
that such alternatives present a great potential for that purpose. A recent feasibility study demonstrated for 
example that engineered skin constructs were capable of detecting low levels of irritants in medical device 
extracts94. Such studies are substantial assets for the implementation of animal testing alternatives for the 
medical device field because their outcome can be used to justify and boost the initiation of test methods 
validation for that specific use. Aside from in vitro skin models and stem cells, there are some methods that 
have not been validated for any applications so far. Relatively new and emerging methods such as the ones 
referring to organs-on-chips, omics technologies and in silico technologies are some of them156,172,176. 
Nevertheless, their potential is already recognized as enormous for the future and discussions regarding their 
validation and use are actively taking place172,187. A concrete example of such methods is the in silico QSAR 
tool188,187. The validation of specific QSAR models is not an easy task because it can be particularly tricky to 
carry out189 and some essential validation principles still have to be specified (specification of a defined 
endpoint and establishment of an unambiguous algorithm, as examples)176,187,190. Despite these issues, a 
QSAR Toolbox was created in 2008 due to the tremendous capabilities of that method191. This toolbox 
(software application) contains a variety of models and databases that can be used by governments, chemical 
industry and other stakeholders to fill the gaps in toxicity data needed for assessing hazards of 
chemicals191,192. It should be however noted that the use of that Toolbox or other available QSAR databases 
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(e.g. JRC QSAR model Database) is under the responsibility of the end-users193. In other words, the use of 
such resources does not guarantee the acceptance of the models for regulatory purposes but it may be used 
to supplement existing data (e.g. to support new product registration).  In fact, QSAR models are claimed to 
be particularly appropriate for the safety assessment of medical devices. It has been shown for instance that 
QSAR modelling is effective in predicting the carcinogenicity of colorants contained in medical devices194. 
The ability to evaluate such adverse responses through modelling is relevant for the field since colorants 
may leach into the body during clinical use and thus pose a risk to the patient. Computational technologies 
in general may therefore be promising options for the establishment of new strategies for the toxicological 
evaluation of medical devices. Though, their validation, even if delicate, needs to be performed because it is 
a valuable asset to achieve regulatory acceptance. Validation is indeed required by science (best scientific 
practices) and legal requirements, making of validation an essential step for all kind of novel alternatives 
being developed.  
 
8.2.  Test method standardisation  
 
Apart from being validated, test methods must be also standardized. Standardization of a test method 
means that the measurement procedure of this method is established in a standard manner, i.e. that its 
execution, analysis, interpretation and reporting is performed consistently among different stakeholders. 
Standards aim to promote the scientific quality of testing, to guarantee the accuracy of testing procedures 
records, to make relevant the comparison of results between different entities and to encourage the use of 
specific gold standard techniques195. As described in section 4, the standard operating procedures applicable 
to the safety assessment of medical devices are provided by the International Standard Organization (ISO) 
under the ISO 10993 standard series. Currently, no in vitro or computational alternatives are standardized by 
ISO 10993 to replace the recommended in vivo tests for that specific purpose. In vitro skin irritation testing 
for instance is mentioned in ISO 10993-Part 10 only as informative data (see Annexe D of the standard)84. 
ISO 10093-Part 10 expressly states: “The in vitro test for skin irritation has so far been validated only for 
neat chemicals and not for medical device extracts. In order to apply these assays for the testing of irritation 
potential of medical devices, further validation for this specific area is essential. Certain aspects of the 
testing of medical devices, such as extraction techniques and possible low concentrations of chemicals in 
these extracts, can result in adaptations of the testing protocol, such as changing extraction techniques or 
incubation times”84. It is thus clear that standardization of any test method is tightly linked to validation. 
Since validation and standardization are entailed to regulatory acceptance, both procedures are fundamental. 
However, regulatory is a complex and long procedure172,195,196, which also encompasses other crucial tasks 
(peer reviewing, evaluation of data usefulness for risk assessment procedure, gathering of existing 
information …)197. Therefore, significant effort and amount of time are commonly needed to introduce new 
alternatives within a regulatory framework. 
 
8.3.  Animal testing alternatives and 3Rs Principle  
 
Currently, the 3Rs Principle (replacement, reduction, refining) is applied within the medical device 
safety regulatory framework as follow: 
 
• Standardized animal testing procedures (refining)84,85,86,87,88 – to promote good science and ensure that 
specific testing conditions are used, setting the basis of animal welfare practices  
• Definition of sample size (reduction)84,85,86,87,88 – to reduce to a minimum the number of animals used 
while obtaining relevant scientific data 
                                                                                                                                                                                                
The OECD QSAR Toolbox for Grouping Chemicals into Categories, https://www.qsartoolbox.org/ (Webpage accessed on 12 June 
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• Validated and standardized in vitro procedures (replacement/reduction)198 – to avoid or complement 
animal testing data   
• Established animal welfare requirements (refining)92 – to guarantee that animal testing is performed 
humanely (animal care and accommodation), without compromising the scientific quality of research 
and reproducibility of the results 
• Risk assessment and rationalization for using animal testing (reduction)83 – to minimize or avoid the 
use of animal testing if other relevant data are available (replacement) 
 
The stated points demonstrate that the key concept of the 3Rs principle is already implemented within 
the existing framework of medical devices safety testing. To further strengthen this principle, additional 
strategies may be considered. For instance, by focussing on the improvement of the quality of animal testing 
procedures, a better scientific acceptance could be achieved on the one hand, and better animal welfare 
conditions on the other hand (refining and reduction). Another possible approach would be to promote the 
development of non-animal testing alternatives (replacement and therefore general reduction).  Concretely, 
considering alternatives described previously, human reconstructed epidermis could be a promising tool to 
replace rabbit skin irritation test for example, and QSAR prediction to reduce the number of rats used for 
carcinogenicity testing. Diverse strategies can thus be foreseen to further consolidate the 3Rs principle in the 
medical devices testing field. Nevertheless, given the special focus of this thesis on the implementation of 
animal testing alternatives, only final thoughts related to this precise topic are considered below.  
As described above, novel non-animal testing alternatives must be validated and standardized to 
maximize their chance of being regulatory accepted. This tricky and long regulatory acceptance process is a 
clear hurdle that can slow down the further enforcement of the 3Rs principle by means of these alternatives. 
Thus, changes are required to achieve regulatory acceptance in a more efficient way. Some potential 
improvement paths are described below199,200,201,202:  
 
• Effective and transparent explanation of the complex process of regulatory acceptance to achieve a 
better understanding on the factors influencing regulatory acceptance.  
• Improvement of the communication and cooperation between stakeholders, i.e. scientists, regulatory 
authorities and industries, to optimize the process of regulatory acceptance and support the alignment 
on set requirements  
• Promotion of data sharing between stakeholders to have a comprehensive view on the topic and avoid 
that studies are unnecessary repeated  
• Encouragement of legislation harmonization to avoid regulatory acceptance discrepancies between 
requirements from different geographical areas 
• And finally, grant synergistic, congruent and global effort (time, money, resources, projects …) for 
the implementation of non-animal alternatives  
 
Those aspects may optimize the process related to the implementation of animal testing alternatives 
and contribute to the establishment of a more ethical testing system applied for regulatory purposes. 
Provided the advanced scientific knowledge available and the pressure set by the global society, there is a 
clear need for that process to be actively and more successfully enforced.  
 
9. Conclusion 
 
The safety assessment of medical devices prior to their marketing is an essential step to guarantee 
public safety and health. Currently, a significant part of this assessment relies on animal models. 
Nevertheless, the use of such models can run into a series of difficulties, such as their effectiveness and 
reliability in correlating human toxicity responses, their price, their time-consumption and their ethical 
concern. Due to these issues, non-animal alternatives have started to be developed to bypass animal testing. 
                                                          
198 ISO 10993-5,  Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity, International Organization for 
Standardization (2009) 
199 Schiffelers W. A. M.-J. et al., Regulatory Acceptance and Use of 3R Models: a Multilevel Perspective, ALTEX (2012), Vol. 
29(3), 287-300 
200 Schiffelers W. A. M.-J. et al., Regulatory acceptance and use of 3R models for pharmaceuticals and chemicals: Expert opinions 
on the state of affairs and the way forward, Regulatory Toxicology and Pharmacology (2014), Vol. 69(1), 41-48 
201 Ashton R. et al,. State of the Art on Alternative Methods to Animal Testing from an Industrial Point of View: Ready for 
Regulation? ALTEX (2014), Vol. 31(3), 357-363 
202 Knight A. Non-Animal Methodologies within Biomedical Research and Toxicity Testing, Altex (2008), Vol. 25(3), 213-231 
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The development of such alternatives constitutes an inter-disciplinary field involving scientists with various 
backgrounds (physicians, biologists, chemists, mathematicians …) and offers valuable testing perspectives 
for the future. In fact, these alternatives are claimed to be cheaper, faster, ethical and more reliable than their 
animal counterparts. The most promising approaches are mainly based on tissue and cell culture, micro-
technologies and computational modelling. However, the tricky validation, standardization and regulatory 
acceptance of these strategies make their implementation within the regulatory framework of medical 
devices particularly difficult. To boost their use within this context, primordial concepts shall be collectively 
enforced: cooperation, coordination, communication and most of all, commitment of all stakeholders 
(scientists, regulatory approval bodes and industries). Knowing that animal studies may paint a misleading 
picture due to their low capability in predicting human responses and consequently pose a risk to patients, it 
became clear that the successful implementation of non-animal alternatives should be considered as a key 
priority and that the resources and effort needed to achieve this goal must be engaged without further delay.  
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